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DNA exists in a compact structure, known as chromatin. Chromatin enables a cell to 
compact its DNA into an individual cell, however, it limits the ability for regulatory proteins to 
access the underlying DNA. The cell has devised mechanisms to overcome this, including the 
covalent modification of histone tails and the use of ATP-dependent chromatin remodelers. The 
bromodomain-acetyl (BD-Ac) interaction is one of the most widespread interactions that links 
covalent modifications to a biological response. The work in this dissertation focuses on gaining 
a better understanding of how multiple BDs engage acetylation, how loss of the BD module can 
alter chromatin structure, and lastly, how the BD-Ac interaction can be targeted for cancer 
therapeutics. We focused on a subunit of the PBAF chromatin remodeling subunit, PBRM1, that 
is frequently mutated in clear cell renal cell carcinoma. This enabled us to simultaneously 
assess how a BD interacts with chromatin and the effect of mutating BDs on chromatin 
interactions, while gaining insight into how PBRM1 loss may be driving tumorigenesis. We show 
that PBRM1 BD2 and BD4 are the primary BDs responsible for mediating interactions with 
transcriptionally active regions of the genome through binding to H3K14ac and H3K4me3. The 
neighboring BDs enhance (BD1, BD5) or inhibit (BD3) binding of these primary BDs, while 
mutations within these BDs attenuate PBRM1 chromatin interactions. Loss of PBRM1 alters 
chromatin organization and enhancer maintenance, resulting in altered gene expression. 
Because the BD-Ac interaction is frequently disrupted in cancers, inhibitors of this interaction 
were developed. In the last part of this work we examine the genome-wide effect of histone 
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deacetylase inhibitors (HDACi) on H4 acetylation (H4ac) and targeting of the BD-containing 
protein, BRD4. HDACi preferentially target regions of the genome with preexisting acetylation, 
most notably gene bodies. Highly transcribed genes were most affected by HDACi, with 
increased H4ac and BRD4 binding in the gene bodies. Together these findings will help future 
studies better understand how multiple reader domains engage chromatin and how disruption of 
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CHAPTER 1: INTRODUCTION 
1.1 Chromatin Structure and Organization 
In eukaryotic cells, DNA is packaged into a compact structure, known as chromatin. 
Nucleosomes are the fundamental repeating unit of chromatin that is made up of 146 base pairs 
of DNA wrapped around a histone octamer consisting of two molecules each of H2A, H2B, H3 
and H4 (1). The histone proteins are positively charged, allowing them to tightly bind to 
negatively charged DNA. Adjacent nucleosomes coil upon one another via linker DNA, allowing 
compaction of DNA into a single cell. Each histone protein contains a central globular domain 
and unstructured C- and N-terminal tails that can be post-translationally modified.  
The compact nature of chromatin hinders accessibility of regulatory proteins to the 
underlying DNA. To overcome this, the cell has devised mechanisms to regulate chromatin 
structure that helps control access to the underlying DNA sequence (2). The ability to selectively 
regulate chromatin structure, enables a cell to alter chromatin to be more or less accessible to 
select machinery in designated genomic intervals. Chromatin structure is regulated by two 
classes of enzymes, histone modifying enzymes and ATP-dependent nucleosome remodelers.   
 
1.2 Histone post-translational modification of chromatin  
Covalent post-translational modification (PTM) of the eight N-terminal histone tails is a 
mechanism for regulating chromatin structure. There are currently 17 different known types of 
histone modifications, including acetylation, methylation and phosphorylation. The number of 
histone PTMs is continually growing due to the heightened sensitivity of mass spectrometry (3). 
Different regions of the genome are marked by different histone PTMs or combinations of 
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PTMs, helping to demarcate different transcriptional domains (4). Promoters are often marked 
by acetylation and H3K4me3 (4), while active enhancers are marked by H3K4me1 and 
H3K27ac (5–8). In contrast, transcriptionally repressed regions of the genome are marked by 
H3K9me3 (9). Importantly, active and repressive marks are not always mutually exclusive, as 
demonstrated by the presence of bivalent domains that have both repressing and activating 
histone PTMs. Histone PTMs can regulate chromatin structure through direct and indirect 
means. They can directly affect chromatin structure by disrupting the noncovalent interactions 
between DNA and chromatin (1, 10). This often occurs by altering the charge of the amino 
acids. Histone PTMs can also regulate chromatin structure through an indirect means by 
providing binding sites for regulatory proteins (11). 
 
1.3 Histone code hypothesis 
The histone code hypothesis, presented nearly two decades ago, proposed that histone 
PTMs establish distinct chromosomal domains and function as a map recognized by non-
histone proteins via specialized domains, to target complexes to select regions of the genome 
(12). It was originally hypothesized that a distinct transcriptional output would result from each 
histone PTM or combination of PTM being bound by a specific reader domain. In subsequent 
years, however, studies have found the histone code hypothesis to be more complex than 
originally proposed. Work focused on elucidating the histone code found that the histone code is 
redundant, being that the same histone modification can be recognized by multiple reader 
domains and that a single reader domain can recognize multiple PTMs (13, 14). Additionally, 
studies have demonstrated that binding by a reader domain can occur across a single tail or 
multiple tails in an intranucleosomal manner (15). While the past two decades has been marked 
by a multitude of studies examining the relationship between histone PTMs and reader proteins, 
there is still much to be elucidated.  
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Histone modifying enzymes 
There are two types of histone modifying enzymes, ‘writers’ and ‘erasers’, that operate in 
an opposing manner to  regulate histone PTMs. ‘Writer’ proteins are responsible for 
incorporating PTMs onto histone tails. They are often part of a larger multisubunit complex that 
contains multiple specialized domains, including domains that recognize other histone PTMs. In 
contrast, ‘eraser’ proteins are responsible for removing histone PTMs from histone tails. Both 
‘writer’ and ‘eraser’ proteins are divided into classes based on the histone modification they 
affect.  
 
Readers of histone modifications 
The histone PTMs laid onto chromatin by histone modifying enzymes are interpreted by 
reader proteins that harbor specialized domains that recognize specific histone PTMs or 
combinations of PTMs.  There are many different types of reader domains that recognize 
histone PTMs including, bromodomains, chromodomains, and PHDs. Using these specialized 
domains, proteins, are targeted to specific genomic sites through direct interactions with histone 
tails. The reader proteins contain a cavity or surface groove in order to bind the modified histone 
residue. They also interact with the sequence flanking the modified amino acid residue to 
provide additional binding specificity (16). Reader proteins make up a wide array of proteins 
involved in various biological processes. Unlike ‘writers’ and ‘erasers’, however, the reader 
domains are redundant being that multiple types of domains can recognize the same 
modifications.   
 
1.4 Acetylation  
Acetylation is one of the most well studied and widespread histone modifications. Lysine 
acetylation can directly affect chromatin structure by neutralizing the positive charge on lysine 
residues, affecting both protein-protein interactions and protein-DNA interactions (17, 18). The 
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destabilization of these interactions results in increased chromatin accessibility. Acetylation is 
associated with gene activation as it is enriched in transcriptionally active regions of the 
genome, including enhancers and promoters. It is involved in a variety of processes, including 
transcription, metabolism and cell signaling.  
 
Acetyl modifiers: HATs and HDACs 
Acetylation of histones is a highly dynamic process that is regulated by two families of 
enzymes: histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs catalyze 
the addition of acetyl moieties to the e-amino group of lysine side chains on histone tails using 
acetyl-CoA as a cofactor. There are more than 18 different mammalian HATs identified that are 
divided into three families based on homology (GNAT, MYST and p300). HATs generally 
function as part of a larger multi-subunit complex that works to promote gene transcription(19). 
In contrast, HDACs remove acetyl groups and restore the positive charge on the histone side 
chain. HDACs are more diverse than HATs and are subdivided into four classes (I-IV) based on 
their homology to their yeast counterparts (20). HDACs are commonly associated with gene 
repression due to the removal of acetyl moieties from chromatin. A tightly regulated balance 
between HATs and HDACs enables controlled acetyl levels and in return, regulated gene 
expression. The discovery that p55/Gcn5, a histone acetyltransferase, could promote gene 
activation was a landmark discovery that linked modification of histones to the transcription 
process (21).  
 
1.5 Bromodomains as readers of acetylation 
A major landmark in proposing the histone code hypothesis was the discovery of the 
bromodomain (BD) module as an acetyl-lysine reader motif (13). There are 61 BDs in the 
human genome comprising 46 diverse proteins, including HATs and ATP-dependent chromatin 
remodelers (22). Structure based alignments have clustered these BDs into eight families. The 
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overall sequence composition of a BD varies substantially, however, they exhibit a conserved 
structural fold, that comprises a left-handed bundle of four alpha helices (aZ, aA, aB, aC) linked 
by diverse loop regions (ZA and BC loops). The alpha helices come together to form a binding 
pocket for histone tails. Binding to acetylated histone peptides has been shown to be mediated 
primarily through a highly conserved asparagine residue within the hydrophobic binding pocket 
(22, 23). While BDs do share a conserved structural fold, they recognize a wide-array of 
acetylated binding partners, likely dictated by the residues surrounding the Kac binding site (22).   
Many BDs act with other protein-interaction modules, including other BDs, PHD, BAH, 
MBD, PWWP and extra-terminal domains (24). The binding affinity of individual BDs is often 
weak as demonstrated by low binding affinities (25).  This suggests that BDs likely function in 
tandem to enhance their binding affinity and/or specificity (15, 24). Multiple proteins have 
demonstrated multivalent binding interactions. Taf1, for example, contains two BDs that bind a 
single histone H4 tail at two different residues (26). In addition, BPTF, a member of the NURF 
chromatin remodeling complex, has been shown to bind across tails, binding H4K16ac through 
its BD and H3K4me3 through its PHD domain (15). The linker residues between the reader 
domains can help dictate binding arrangements. The BET family of BDs, for example, contain a 
long flexible linker between the two tandem BDs that allows for conformational plasticity. This 
enables the two BDs to simultaneously engage two acetylated lysine residues (27, 28). The 
multivalent nature of individual BDs and their function when in tandem with neighboring BDs has 
proved the histone code hypothesis to be more challenging to decode than originally 
hypothesized. Assessing the binding of individual BDs in the context of neighboring domains is 
now seen as important for properly identifying the binding partners of an individual domain.  
 
1.6 BD containing proteins and gene regulation 
BD-containing proteins makeup a wide array of diverse proteins, that through 
interactions with chromatin, regulate gene expression. BDs make up proteins involved in many 
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biological processes from histone modifying enzymes that both directly and indirectly regulate 
expression of genes to chromatin remodelers that recognize the histone PTM and remodel the 
associated chromatin. 
 
BD proteins as part of ATP-dependent chromatin remodeling complexes  
BD-containing proteins are often part of a larger, multisubunit complex, including 
chromatin remodeling complexes. ATP-dependent chromatin remodelers are the second 
mechanism for regulating chromatin structure. They rely on the energy from ATP hydrolysis to 
facilitate the restructuring of chromatin, through the sliding or ejection of nucleosomes (29, 30). 
There are four major subfamilies of chromatin remodelers (SWI/SNF, INO80, ISWI, and CHD). 
Each complex contains shared and distinct BD-containing subunits that target the complexes to 
specific regions of the genome and regulate chromatin compaction and decompaction. 
Chromatin remodelers, thus, play an important role in cellular processes, including transcription, 
replication and DNA repair by giving access to underlying DNA. 
The SWI/SNF (switch/sucrose non-fermenting) complex is a multi-subunit complex that 
contains multiple BD-containing proteins involved in various functions. In humans, there are two 
core proteins, BRG1 and BRM, that use the energy from ATP-hydrolysis to modulate 
nucleosome positioning. Both proteins contain C-terminal BD modules that are capable of 
binding acetylated H3 and H4 histones.  The PBAF (polybromo and BRG1 associated factor) 
SWI/SNF remodeling complex distinctly contains Polybromo-1 (PBRM1) that contains six 
bromodomains and is, therefore, thought to function as the targeting subunit of the PBAF 
complex.   
 
BD proteins as histone recognition scaffolds 
BD-containing proteins also function as scaffolds that recruit various complexes to 
specific regions of the genome. The BET (bromodomain and extra-terminal) family of proteins 
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consisting of BRD2, BRD3, BRD4, and BRDT has arisen as scaffolding proteins important for 
transcription. They are characterized by having two BDs and an extra-terminal (ET) domain. 
BET proteins dock onto acetylated chromatin via the dual BDs and recruit various members of 
the transcriptional machinery via the ET domain.  BRD4 offers insight into the tight regulation of 
BD-containing proteins and gene expression. Recruitment of BRD4 is a critical step for 
transitioning from transcriptional initiation to elongation (31, 32). Binding of BRD4 to H4 
acetylated promoters leads to recruitment of the positive elongation factor (P-TEFb) releasing 
paused RNA Pol II into transcriptional elongation through its kinase activity (33). Because of the 
tight linkage between acetylation and gene expression, deregulation of acetylation can have 
widespread consequences, including the development of cancer.  
 
1.7 Disruption of the bromodomain-acetyl interaction in cancer 
The bromodomain-acetyl interaction is one of the most widespread interactions, involved 
in almost all biological processes. Disruption of either the acetyl modifiers or the bromodomain 
readers can result in altered chromatin structure and have widespread consequences, that 
ultimately result in oncogenesis. HATs and HDACs are often aberrantly expressed in cancer, 
with both hypoacetylation and hyperacetylation having been observed in human tumors. 
Additionally, dysregulation of BD-containing proteins is also frequently seen in various cancers, 
demonstrating the importance of both acetylation and BD function in maintaining cellular 
homeostasis.  
 
Dysregulation of acetyl modifiers in cancer 
The discovery that HATs acetylate histones was quickly followed by the discover of their 
role in cancer. Several HATs, including CBP and GCN5, have been implicated in the 
development of various cancers (34, 35). In acute lymphoid leukemia (ALL), over 18 percent of 
patients have mutations in the HAT domain of CBP, inactivating its catalytic activity (36). In 
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multiple cancers, including breast (37), non-small lung (38), prostate (39) and hepatocellular 
carcinoma (40), overexpression of the HAT, p300, is observed.  The dosage of HATs also plays 
a role in cancer development(41).  
HDACs have also been shown to be overexpressed in multiple cancer types (42), 
including gastric  (43), colon (44), breast (45), and prostate (46), suggesting that overexpression 
of HDACs and subsequent deacetylation is critical in the development of cancers. Many 
leukemias demonstrate chimeric fusions between HDACs and other proteins to mediate 
aberrant gene silencing, leading to the development of cancers(47). Interestingly, inhibitors of 
HDACs showed reversal of aberrant gene expression induced from the upregulation of HDACs. 
The tumor suppressive effect of HDAC inhibition led to the development of HDAC inhibitors 
(HDACi).  
 
Dysregulation of bromodomain-containing proteins in cancer 
In addition to mutations in the ‘writers’ and ‘erasers’ of acetylation, dysregulation of BD-
containing proteins is common among cancers. A study assessing 21 different pediatric cancer 
subtypes identified recurrent mutations in 21 of the BD containing proteins (48). BET proteins 
are frequently involved in cancer (49). Genetic rearrangement of BD-containing proteins has 
been linked to aggressive cancers, such as BRD4-NUT in NUT midline carcinoma (50). 
Overexpression of BD-containing proteins, such as TRIM24 was shown to promote tumor 
growth and was linked to poor overall survival in glioblastomas (51). Interestingly, however, the 
effect of BD mutations is context dependent. In some cases, mutation of the BD-containing 
protein promotes tumor development, while in other cases it acts as a tumor suppressor. This 
makes studying BDs challenging, however, could provide a high degree of drug targeting 
specificity.  The dysregulation of BD-containing proteins in cancer, and the hydrophobic pocket 
of BDs, made it an ideal target for drug therapeutics. 
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1.8 Targeting the bromodomain-acetyl interaction for therapeutics 
The common dysregulation of acetylation and BD-containing proteins in cancers led to 
the development of inhibitors of both acetyl modifiers, such as HDACi, and BD-containing 
proteins, such as BET inhibitors (BETi).   
 
HDAC inhibitors 
The dynamic nature of acetylation and its role in gene expression by modulating 
chromatin structure and directing chromatin remodelers makes it an ideal therapeutic target. 
Studies demonstrating the tumor suppressive effect of HDAC inhibition led to the development 
of HDAC inhibitors (HDACi). HDACi can target all types of HDACs (pan-inhibitors) or selectively 
inhibit specific classes of HDACs. There are currently many HDACi approved by the United 
States Food and Drug Administration (FDA) or in phase 2 and 3 of clinical trials for the 
treatment of various cancers. FDA approved HDACi, include Vorinostat, Belinostat and 
Panobinostat. While these drugs are widely used in the clinic, little is known about their 
mechanism of action. A better understanding of where HDACi target their targets could provide 
evidence for more targeted therapies.  
 
BET inhibitors  
The properties of a BD allow for the design of pharmacologically active molecules that 
can bind the BD binding pocket and inhibit it from binding its target site. While BDs share a 
conserved structural fold, the residues making up the binding pocket and the loop regions are 
highly diverse. This allows for the development of highly specific BD inhibitors. The frequent 
dysregulation of BET proteins in cancers provided a rationale for targeting BET proteins as a 
means of new anticancer drugs. The development of the BET inhibitor (BETi), JQ1, provided the 
first means of evidence that BETi could function as an anticancer agent.    
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1.9 Concluding remarks and contributions of this work 
A fine balance exists between proteins responsible for covalently modifying the genome, 
removing the covalent modifications, and reading these modifications in order to relay a 
response. There is still much to be understood about how an effector protein recognizes its 
mark and the consequence of losing the effector protein. Many of these effector proteins are lost 
or mutated in cancers, suggesting an important role in maintaining cellular homeostasis. Studies 
have begun targeting both the effector protein and ligand. The work described in this 
dissertation furthers our understanding of the interactions between histone PTMs and reader 
proteins, and the effect of disrupting this interaction.   
The BD-acetyl interaction is one of the most widespread and studied interactions. 
However, there is still much unknown about how multiple bromodomains engage acetylation 
and the consequence of disrupting this interaction. Studies have demonstrated the frequent 
mutation of proteins containing BDs and the modifiers responsible for regulating levels of 
acetylation. Because of the widespread nature of the BD-acetyl interaction, disrupting the BD-
acetyl bond can have widespread consequences, making both the BD and acetyl potential 
therapeutic targets. This dissertation seeks to better understand (1) how multiple BDs function 
in tandem to mediate interactions with acetylation (2) how BD mutations affect chromatin 
interactions (3) how loss of a bromodomain containing subunit of a chromatin remodeler alters 
chromatin structure and (4) how altering acetylation through histone deacetylase inhibitors alters 
acetylation and bromodomain targeting genome-wide.   
Chapter 2 focuses on how a reader domain mediates interactions with chromatin 
through multiple bromodomains. We examine the role of the six tandem bromodomains of 
PBRM1 to interact with chromatin and the result of mutating individual BDs on chromatin 
interactions. First, we identified the BDs responsible for interacting with chromatin and the 
modifications recognized by these BDs. We then assessed how the surrounding BDs affected 
these interactions. We then introduced mutations within the critical BDs of full-length PBRM1 
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and assessed the effect on chromatin interactions and cell proliferation.  We show that PBRM1 
mediates interactions with chromatin through BD2 and BD4 which is enhanced by BD1 and 
BD5, respectively. Further, we demonstrate that these interactions with chromatin are mediated 
through H3K14ac and/or H3K4me3.  
In Chapter 3 we explore how loss of a reader protein, PBRM1, affects chromatin 
organization and examine the effect it has on gene regulation. We establish how PBRM1 loss 
affects chromatin globally and then assess its effect on individual nucleosomes. We assess how 
PBRM1 loss affects enhancers and the result on gene transcription associated with PBRM1 
loss. We show that PBRM1 helps to maintain proper enhancers and when lost results in the 
shifting of nucleosomes around enhancers, helping to mediate gene transcription.  
In Chapter 4 we describe how altering a covalent modification through HDAC inhibitors 
affects global acetylation and the effect on effector protein targeting, specifically BRD4. We 
establish how HDAC inhibitors affect H4 acetylation using both a proteomics and genomics 
approach and demonstrate quantitatively where these changes are occurring. Next, we illustrate 
proteins that recognize H4 poly-acetylation and focus on changes in BRD4 targeting as a result 
of the changes in H4ac after HDACi. This chapter demonstrates that HDAC inhibitors target 
gene bodies in order to act as a sink for BRD4.  
 
1.10 Thesis Contributions 
The work described here was part of a collaborative effort between multiple labs. The 
project described in Chapter 2 was a collaboration between the labs of Ian Davis and Brian 
Strahl. The peptide array analyses were performed by Dr. Erin Shanle. Chapter 3 was a 
collaborative project between the labs of Ian Davis and William Y Kim. Dr. Janet Yee Man 
Leung performed the experiments for the RNA-seq data. Austin Hepperla analyzed the data for 
the MNAse-seq, ChIP-seq and RNA-seq. Chapter 4 was in collaboration with the labs of Ian 
Davis, Brian Strahl, Ben Garcia, and David Allis. The proteomic studies were performed by the 
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labs of Ben Garcia and David Allis. The experiments on HDACi and BRD4 targeting were 
performed by Dr. Erin Shanle and the RNA-seq data collection was performed by Dr. Abid 

















CHAPTER 2: POLYBROMO-1 (PBRM1) BROMODOMAINS VARIABLY INFLUENCE 




Chromatin remodelers use bromodomains (BDs) to recognize histones. Polybromo-1 
(PBRM1 or BAF180) is hypothesized to function as the nucleosome-recognition subunit of the 
PBAF chromatin-remodeling complex and is frequently mutated in clear cell renal cell carcinoma 
(ccRCC). Previous studies have applied in vitro methods to explore the binding specificities of 
the six individual PBRM1 BDs. However, BD targeting to histones and the influence of 
neighboring BD on nucleosome recognition have not been well characterized. Here, using 
histone microarrays and intact nucleosomes to investigate the histone-binding characteristics of 
the six PBRM1 BDs individually and combined, we demonstrate that BD2 and BD4 of PBRM1 
mediate binding to acetylated histone peptides and to modified recombinant and cellular 
nucleosomes. Moreover, we show that neighboring BDs variably modulate these chromatin 
interactions, with BD1 and BD5 enhancing nucleosome interactions of BD2 and 4, respectively, 
while BD3 attenuated these interactions. We also found that binding pocket missense mutations 
in BD4 observed in ccRCC disrupt PBRM1–chromatin interactions and that these mutations in 
BD4, but not similar mutations in BD2, in the context of full-length PBRM1, accelerate ccRCC 
cell proliferation. Taken together, our biochemical and mutational analyses have identified BD4 
as being critically important for maintaining proper PBRM1 function and demonstrate that BD4 
                                               
1 This research was originally published in the Journal of Biochemistry. Mariesa J. Slaughter, Erin K. 
Shanle, Andrew W. McFadden, Emily S. Hollis, Lindsey E. Suttle, Brian D. Strahl, Ian J. Davis. 
Polybromo-1 (PBRM1) bromodomains variably influence nucleosome interactions and cellular function. 
Journal of Biological Chemistry. 2018;293(35): 13592-13603 © the American Society for Biochemistry 
and Molecular Biology. 
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mutations increase ccRCC cell growth. Because of the link between PBRM1 status and 
sensitivity to immune checkpoint inhibitor treatment, these data also suggest the relevance of 




Chromatin compaction regulates DNA accessibility. In response to stimuli, cells alter 
chromatin through covalent modification of histones and the activity of chromatin remodelers. ε-
N-acetylation of lysine residues is one of the most abundant histone tail modifications and is 
often associated with transcriptional activation (52). The interaction of proteins with acetylated 
histones is typically mediated by evolutionarily conserved bromodomains (BDs) (13, 53). Sixty-
one BDs are found across a diverse array of human proteins, including many chromatin 
modifiers. BDs are made up of four alpha-helices linked by two loops to form a hydrophobic 
cavity. Although BDs share a conserved structure, they display large sequence variation and 
recognize a range of acetylated histones (22). A conserved asparagine at the C-terminus of 
helix αB mediates interaction with the acetyl group (13, 23, 54).  
The original histone code hypothesis proposed that protein interactions with chromatin are 
mediated through recognition of specific patterns of histone posttranslational modifications 
(PTMs) (12). The functional redundancy and promiscuous binding of BDs to acetylated lysine 
residues suggest a multivalent model in which linked domains mediate cooperative interactions 
with combinations of histone PTMs (24).  Significantly, BDs often exist in tandem with other 
chromatin recognition domains, most commonly a PHD or second BD (22, 24), suggesting that 
multivalency may be common in proteins that contain these domains. Most studies of BDs have 
focused on individual domains, without consideration for the effect of neighboring reader 
domains. However, several studies support that cooperative interactions can mediate 
multivalent interactions (24, 26, 55, 56). For example, BPTF, a member of the NURF chromatin 
remodeling complex, contains a BD and PHD that mediate interaction with nucleosomes 
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harboring H3K4me3 and H4K16ac (15). Tandem domains can also demonstrate auto-regulatory 
function (57). Because of relationships between these protein domains, consideration of BD 
context is critical when assessing the targeting specificity of these proteins.   
 
PBRM1 (Polybromo-1, PB1, BAF180), a member of the PBAF SWI/SNF chromatin-
remodeling complex, is unique among chromatin reader proteins as it contains six tandem BDs. 
No other protein contains more than two BDs, and other components of the SWI/SNF complex 
contain at most a single BD. The presence of multiple BDs suggest that PBRM1 may act as the 
nucleosome recognition subunit of the PBAF complex (58). PBRM1 is mutated in approximately 
40% of clear cell renal cell carcinomas (ccRCCs) (59, 60). However, the role of PBRM1 loss in 
ccRCC development remains unclear. How the multiple BDs of PBRM1 mediate chromatin 
interaction would provide insights into the function of PBRM1 and could suggest a role for 
PBRM1 mutation in the development of ccRCC.  
Previous studies have explored the binding of individual PBRM1 BDs to histones tail 
sequences using synthetic peptides (22, 54, 61, 62).  However, since biologically relevant 
recognition of the histone tails is in context of a multimeric nucleosome, synthetic peptides may 
offer a restricted representation of native binding interactions. Also, since these studies were 
performed with individual BDs, the relationship between neighboring BDs on histone recognition 
has remained unexplored. The reliance on synthetic peptides, experimental variation and a low 
affinity for individual BDs to acetyl lysine residues (62) have limited the robustness and 
consistency of prior studies.  
In this study, we explored the binding characteristics of the six PBRM1 BDs, both 
individually and in tandem, to histone peptides and to intact nucleosomes. We assessed the 
impact of kidney cancer-associated mutations in the context of individual and tandem BDs, and 
full-length PBRM1 to highlight regions within the BDs that are critical for PBRM1 function. We 
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observed selective binding of individual BDs as well as the influence of neighboring BD on 




2.3.1 Amino acid sequence classifies PBRM1 bromodomains 
We compiled PBRM1 mutations observed in kidney cancers from several studies, including 
The Cancer Genome Atlas KIRC project (63–66). We focused on the nonsynonymous missense 
mutations (17% of total) based on the hypothesis that these mutations would be located in 
cancer-relevant functional domains in PBRM1. In contrast to frameshift mutations that were 
distributed throughout the gene, missense mutations tended to cluster within the BDs, 
specifically in and proximal to BD4 (p < 0.05 by permutation) (Fig. 2.1A). BD4 harbored five 
missense mutations, including two at highly conserved amino acids (Y580C and N601K). No 
missense mutations were identified in BD3. One mutation was identified in BD2, I252R, a non-
conserved residue. 
We then evaluated the amino acid sequence conservation between the six PBRM1 BDs. 
Hierarchical clustering analysis was performed (67). The comparison included the BDs from 
SMARCA4 (BRG1) and SMARCA2 (BRM), the other BD-containing components of the 
SWI/SNF complex. The BDs segregated into three clusters (Fig. 2.1B). BD2 and BD4 shared 
the greatest sequence similarity (50.7%) and grouped together with the SMARCA2 and 
SMARCA4 BDs. BD1 clustered with BD3 (42.3%), whereas BD5 clustered with BD2 (39%) and 
BD4 (42%). BD6 was most distinct, exhibiting less than 26% sequence similarity to the other 
BDs. We next identified those amino acids that influenced clustering (Fig. 2.1C). Alignment of 
the six BDs revealed that seven amino acids were conserved across all BDs. Among these was 
a tyrosine residue within the AB-loop that is the site of a missense mutation in ccRCC (Y580C in 
BD4). Because BD6 shares the least sequence similarity to the other BDs, we focused on 
residues conserved between BD1-5. Residues conserved between these BDs are enriched in 
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the ZA-loop and termini of helix αB—regions that help form the hydrophobic pocket. Amino 
acids that distinguish BD2 and BD4 were clustered within the ZA-loop, αA and αC helices.  
To determine how amino acids may direct the function of each BD, we mapped conserved 
amino acids onto a published NMR solution structure of the BD2/H3K14ac complex (Fig. 
2.1D)(62). Conserved residues cluster in and around the BD binding pocket. Three of the 
residues shared uniquely by BD2 and BD4 reside within the region of αC helix that forms the 
hydrophobic pocket. These residues are proximal to the conserved asparagine that likely 
mediates interaction with acetylated H3K14 and have been shown to help establish histone 
interactions (62). Two amino acids shared by BD2 and BD4 are in the ZA-loop predicted to be 
near the amino terminus of the histone tail. In contrast, BD1, BD3 and BD5 share fewer 
conserved residues at regions that interface with the histone tail (Appendix A, Supplementary 






FIGURE 2.1:PBRM1 mutation rate and sequence conservation varies across 
bromodomains. (A) Schematic diagram of PBRM1 marked with missense and frameshift 
mutations found in kidney cancer. (B) Dendrogram demonstrating amino acid sequence 
conservation of PBRM1 and other SWI/SNF complex-associated bromodomains. (C) Sequence 
alignment of PBRM1 bromodomains. Shading and arrows reflect the degree of conservation 
between bromodomains. Residues commonly mutated in ccRCC are shown with red and blue 
text. Bromodomain structural elements marked above the alignments. (D) Conserved residues 
overlaid on an NMR-derived secondary structure of PBRM1 BD2 in association with histone H3 












2.3.2 PBRM1 bromodomain binding specificities reflect variation in primary sequence 
To test for an association between sequence composition and histone recognition, we 
examined the binding of each BD to histone PTMs using a microarray platform. The histone 
microarrays consist of >200 synthetic peptides reflecting the core histone tails (H2A, H2B, H3 
and H4) modified with one or more known PTMs (68). GST-tagged BDs were incubated with the 
arrays and interactions were quantified with a fluorescent anti-GST antibody (Fig. 2.2A). Binding 
was rank ordered relative to the highest signal in the array. BD2 and BD4 recognized a similar 
pattern of H3 PTMs, with a marked preference for peptides containing H3K14ac alone or in 
combination with other acetylated amino acids. Acetylation at other sites was not associated 
with BD2 or BD4 binding. BD1, BD3 and BD5 weakly interacted with H3K14ac modified 
peptides when in combination with H3K4ac and H3K18ac. Minimal binding of BD2 and BD4 to 
the unmodified H3 tail was detected, demonstrating that binding is to the histone tail 
modification, not the tail itself. BDs 1 and 5 weakly bound to various mono-acetylated peptides, 
including H3K18ac. However, this binding intensity was similar to that of the unmodified tail. 
BD6 demonstrated minimal binding to all peptides. The overall pattern of binding to modified H3 
histone tail peptides reflected their sequence conservation (Fig. 2.1B), suggesting that the BD 
sequence determines the function of the individual domains.   
 
2.3.3 BD2 And BD4 mediate primary interactions with H3 tails 
Since the interaction of BDs with histone tail peptides may only partially reflect how histone 
tails are recognized in the context of an intact nucleosome  (22, 54, 61, 62), we then assessed 
BD association with gradient-purified mononucleosomes from micrococcal nuclease (MNase)-
treated nuclei (15) (Fig. 2.2B). We used a range of enzyme concentrations to ensure that the 
pool of nucleosomes would broadly reflect chromatin states (Appendix A, Supplementary Figure 
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A.2A). Purified nucleosomes contained all four core histones (Fig. 2.2C). Bead-bound GST-
tagged BDs were incubated with the cellular nucleosomes, and enriched histone PTMs were 
detected by Western blot analysis (Fig. 2.2D).  We found that BD2 and BD4 strongly interacted 
with nucleosomes, whereas BD5 only weakly bound nucleosomes. No binding was detected for 
BD1, BD3, and BD6.  
We then identified the PTMs that were enriched on BD-bound nucleosomes (Fig. 2.2E). 
Because individual nucleosomes likely harbor multiple PTMs, observed PTMs may directly or 
indirectly mediate BD binding. Nucleosomes bound by BD2 and BD4 were preferentially marked 
by H3K14ac, consistent with the peptide results. Bound nucleosomes were also enriched for 
H3K4me3. Since binding to H3K4me3 was not observed on the peptide array, we hypothesized 
that BD-bound nucleosomes harbor both H3K14ac and H3K4me3, with binding primarily 
mediated by acetylation. The use of mononucleosomes excluded the possibility that binding was 
mediated by neighboring nucleosomes. To directly test the effect of each PTM on nucleosome 
binding, we then used unmodified recombinant nucleosomes those exclusively modified by 
either H3K14ac or H3K4me3 (Fig. 2.2F, Appendix A, Supplementary Figure A.2B-C). No BD 
bound the unmodified nucleosomes. Only BD2 and BD4 bound nucleosomes harboring 
H3K14ac. Limited binding to H3K4me3-marked nucleosomes was also detected. Because 
binding to H3K4me3 was unexpected, we assessed the relative binding affinity to H3K14ac and 
H3K4me3 by varying the concentration of NaCl in the binding reaction (Fig. 2.2G). In contrast to 
unmodified nucleosomes for which interaction was completely disrupted by 150 mM NaCl, BD2 
and BD4 interaction with H3K14 acetylated and H3K4 trimethylated nucleosomes persisted to 
300 mM NaCl, although increased binding to H3K14ac-modified was observed. Taken together, 
these data demonstrate that, in vitro, BD2 and BD4 are able to interact with nucleosomes 
marked with a wide range of PTMs but are mediated through a direct interaction with H3K14ac 
and/or H3K4me3.  
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FIGURE 2.2: PBRM1 BD2 and BD4 recognize H3K14ac and H3K4me3. (A) Quantification of 
peptide microarray interactions between individual PBRM1 BDs and H3 peptides. Each column 
represents one peptide array. Normalized mean intensities are rank-ordered within each array.  
Dendrogram indicates clustering using Pearson correlation. (B) Agarose gel electrophoresis of 
sucrose gradient fractions. 100 bp ladder is shown, L. Fractions pooled as mono-nucleosomes 
are shown. (C) Coomassie stained SDS-PAGE gel of recombinant nucleosomes and cellular 
extracted nucleosomes. Presence of all four core histones are indicated. (D) Mononucleosomes 
selected by GST-tagged PBRM1 BDs were separated by SDS-PAGE and blotted with 
antibodies that recognize H3 tail PTMs. 2.5% of the total mononucleosome pool was included 
for reference. 25 kDa (purple) and 15 kDa (green) molecular markers are indicated. (E) 
Quantification of signal for BD-associated nucleosomes relative to total nucleosome input 
(AP/input). (F) Unmodified, H3K14ac or H3K4me3 modified recombinant nucleosomes were 
used to select single BDs. Proteins were separated by SDS-PAGE and blotted with anti-GST 
antibody and anti-H3 antibody (input). GST-BD input (1%) is shown. 55 kDa (blue) and 40 kDa 
(orange) molecular markers are indicated. (G) Unmodified, H3K14ac or H3K4me3 modified 
recombinant nucleosomes were incubated with BD2 and BD4 at several concentrations of NaCl. 
Associated proteins were separated by SDS-PAGE and blotted with anti-GST antibody. 55 kDa 
(blue) and 40 kDa (orange) molecular markers are indicated. 
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2.3.4 Neighboring bromodomains influence nucleosome binding 
BDs often exist in tandem with other chromatin reader domains to facilitate binding 
specificity (22, 69). Prior biochemical studies characterizing PBRM1 BD binding specificity have 
examined individual BDs (22, 54, 61, 62).  We hypothesized that neighboring PBRM1 BDs 
would influence BD2 and BD4 binding. To explore this idea, we generated and FPLC purified 
five overlapping tandem BDs (Fig. 2.3A). Circular dichroism (CD) demonstrated similar 
structures for all single and tandem BDs (Fig. 2.3B). Consistent with the results from single BDs, 
only tandem domains that included either BD2 or BD4 bound nucleosomes (Fig. 2.3C). BD5-6 
failed to interact with nucleosomes. Similar to that observed with the individual BDs, the tandem 
BDs preferentially recognized nucleosomes harboring H3K14ac and H3K4me3 (Fig. 2.3D). 
Intriguingly, the combination of BD1 with BD2 and BD5 with BD4 enhanced binding to 
nucleosomes, whereas the combination of BD3 with either BD2 or BD4 decreased binding.  
We then directly compared nucleosome binding of individual BDs with tandem BDs (Fig. 
2.3E). We found that BD1-2 showed enhanced binding over BD2 alone, and BD4-5 showed 
enhanced binding over BD4 alone (Fig. 2.3F). As BD1 and BD5 do not bind nucleosomes 
individually (Fig. 2D), the enhanced binding of BD1-2 and BD4-5 suggests that the BDs must 
cooperate to facilitate histone interactions. Strikingly, the addition of BD3 to either BD2 or BD4 
decreased binding below that observed with the individual BD.  
As before, we then used recombinant nucleosomes to assess binding to nucleosomes 
exclusively modified by H3K14ac or H3K4me3 (Fig. 2.3G). At low salt concentrations, BD1-2 
and 4-5 bound H3K14ac, H3K4me3 and unmodified nucleosomes. BD2-3 and 3-4 weakly 
bound H3K14ac and H3K4me3. Similar to our previous findings, binding of either BD2 or BD4 to 
H3K14ac-marked nucleosomes was attenuated by the presence of BD3. Neither BD3-
containing tandem BD bound unmodified nucleosomes. BD5-6 failed to bind any nucleosomes. 
As before, we varied the salt concentration in the binding reaction (Fig. 2.3H). Increased NaCl 
fully disrupted BD4-5 binding to the unmodified nucleosomes. Binding to H3K14ac and 
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H3K4me3-modified nucleosomes persisted at high salt concentration, although more binding to 
H3K14ac was evident.  These data suggest that, in vitro, BD4-5 can bind either H3K14ac or 
H3K4me3, although binding to H3K14ac is favored.  
 
FIGURE 2.3: Neighboring PBRM1 BDs influence binding of BD2 and BD4. (A) Schematic of 
tandem GST-tagged PBRM1 BD constructs, where G stands for GST. (B) Circular dichroism 
absorbance spectra comparing single (black) and tandem (red) PBRM1 BDs from 190-260 nm 
(C) GST-tagged tandem BDs were used to select sucrose-gradient purified mononucleosomes. 
Associated PTMs were detected by Western blot. 25 kDa (purple) and 15 kDa (green) molecular 
markers are indicated. The input blot for H3K18ac was used in Figure 2.2D. (D) Normalized 
(AP/input) signal is shown for H3-associated PTMs (E) Cellular nucleosome interactions for 
single and tandem BDs were assessed by Western blot. 25 kDa (purple) and 15 kDa (green) 
molecular markers are indicated. (F) Normalized (AP/input) signal is shown. (G) Unmodified, 
H3K14ac or H3K4me3-marked recombinant nucleosomes were incubated with tandem BDs. 
Associated proteins were separated by SDS-PAGE and blotted with anti-GST antibody and anti-
H3 antibody (input). BD input (0.5%) is shown. 70 kDa (pink) and 55 kDa (light blue) molecular 
markers are indicated. (H) Unmodified, H3K14ac or H3K4me3-marked recombinant 
nucleosomes were incubated with tandem BDs in the presence of various concentrations of 
NaCl. Bound proteins were separated by SDS-PAGE and blotted with anti-GST and anti-H3 
(input) antibodies. 70 kDa (pink) and 55 kDa (light blue) molecular markers are indicated. 
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2.3.5 PBRM1 bromodomains interact with the H4 N-terminus 
We unexpectedly observed that several of the PBRM1 BDs interact with H4 tail peptides, 
with the degree of interaction inversely related to acetylation state (Fig. 2.4A). Assayed on the 
peptide microarray, BDs1-5 interacted with the unmodified and monoacetylated N-terminus of 
H4 to various degrees. Limited binding by BDs1-5 to diacetylated H4K5+K12 and H4K8+K16 
was detected. Binding was not detected to tri- and tetraacetylated H4 tails. Unlike binding to the 
H3 tail, the BD binding patterns for H4 did not correspond to sequence conservation, suggesting 
these interactions may occur outside of the conserved binding pocket. To determine whether 
nucleosomes bound by the BDs demonstrated selective enrichment for specific H4 tail 
modifications, we examined three histone H4 modifications: H4K5ac, H4K16ac, and tetra-
acetylated H4 (H4K5ac, K8ac, K12ac, K16ac) (Fig. 2.4B). Nucleosomes bound by both BD2 
and BD4 were enriched for H4K16ac to a greater extent than H4K5ac or H4 tetra-acetyl. 
Differences between the peptide array and the nucleosome pull-downs may be attributed to the 
presentation of the PTM in the context of an oligopeptide rather than an intact nucleosome. We 
then examined enrichment of H4 modifications on cellular nucleosomes bound by the tandem 
BDs (Fig. 2.4C). BD1-2 and BD4-5 tandem BDs demonstrated greater binding compared to 
tandem BDs containing BD3. The tandem BDs also bound nucleosomes enriched for H4K16ac. 
Taken together, our data suggest that BD2 and BD4 are largely responsible for PBRM1 
chromatin interactions through a direct interaction with H3K14ac and possibly a weak interaction 
with H3K4me3. Additionally, we demonstrate that BD1 and BD5 cooperate to enhance these 
binding interactions, potentially through interaction with an unmodified tail, whereas BD3 may 





FIGURE 2.4: PBRM1 bromodomains interact with H4 tail. (A) Quantification of peptide 
microarray interactions between individual PBRM1 BDs and H4 peptides. Each column 
represents one peptide array. Normalized mean intensities are rank-ordered within each array.  
Dendrogram indicates clustering using Pearson correlation. GST-tagged (B) Single BDs and (C) 
Tandem BDs were used to select purified mononucleosomes. Associated H4 PTMs were 
detected by Western blot. Normalized (AP/input) signal is shown. Input mononucleosomes 
(2.5%) are shown. The blots demonstrating input signal for H4K5ac and H4K16ac are 










2.3.6 ccRCC BD4 mutants disrupt histone recognition 
Since BD4 exhibits the highest frequency of missense mutations in ccRCC (Fig. 2.1A) and 
plays an important role in mediating nucleosome interaction, we explored the effect of BD4 
mutations. Two mutations in ccRCC occur at highly conserved residues. Y580 is in the AB-loop 
region that interacts with a conserved aspartate in helix αB and is thought to stabilize the loop-
helix fold (22). N601 is in the hydrophobic cavity that anchors the BD to the histone tail (Fig. 
2.5A) (13, 23). These mutations were generated in the context of an individual BD and the BD4-
5 tandem. CD of the four mutants demonstrated the expected pattern for a highly alpha-helical 
protein, similar to the wild-type protein (Fig. 2.5B). We next assessed the effect of these 
mutations on nucleosome recognition (Fig. 2.5C). Both mutations significantly diminished 
interaction of the BDs with nucleosomes, including nucleosomes harboring H3K14ac, H3K4me3 
and H4K16ac (Fig 5D). Interestingly, BD4 mutations in the context of tandem BD4-5 more 
severely disrupted nucleosome interactions than the mutation in the individual BDs, an effect 




FIGURE 2.5: ccRCC-associated mutations decrease recognition of histone PTMs. (A) 
Missense mutations (Y580C and N601K) were overlaid on the NMR-derived structure. (B) 
Circular dichroism absorbance spectra for BD4 and BD4-5 as well as BD4 and BD4-5 Y580C 
and N601K mutants. (C) PBRM1 BDs and mutants were used to pull down cellular 
mononucleosomes. Bound material analyzed by immunoblot using antibodies against H3 and 
H4 PTMs. 25 kDa (purple) and 15 kDa (green) molecular markers are indicated. (D) Normalized 







2.3.7 PBRM1 BD2 and BD4 are required for chromatin interactions 
We next assessed how mutations in BD2 and BD4 affect chromatin interactions in the 
context of full-length PBRM1. Doxycycline-inducible mutants were expressed in a ccRCC cell 
line (RCC4), which lacks endogenous PBRM1 (Fig. 2.6A). Following PBRM1 induction, proteins 
were extracted from nuclei with increasing NaCl concentrations to assess the effect of mutations 
on chromatin affinity (Fig. 2.6B, C). At a low NaCl concentration, PBRM1 and single mutants 
remained mostly bound to chromatin. Mutation of both BD2 and BD4 (BD2/4), however, 
significantly decreased binding of PBRM1 to chromatin (Fig. 2.6C). By 200 mM NaCl virtually all 
of the BD2/4 mutant was extracted from chromatin, whereas a significant fraction of the BD2 
and 4 single mutants persisted on chromatin (Appendix A, Supplementary Figure A.3).  These 


















FIGURE 2.6: Mutation of BD2 and BD4 decreases chromatin association leading to 
increased cell proliferation (A) Induction of full-length PBRM1 mutants in RCC4 cells by 
doxycycline. Proteins were separated by SDS-PAGE, and PBRM1 expression was detected by 
immunoblot analysis. (B) RCC4 nuclei were collected and extracted with increasing 
concentrations of NaCl. Eluted proteins were separated by SDS-PAGE and PBRM1 levels were 
examined by Western blot analysis (C) Quantification of PBRM1 eluted as a fraction of total 







2.3.8 Mutation of BD2/BD4 increases cell proliferation 
We then assessed the biological consequence of mutations in BD2 and BD4 by expressing 
full-length PBRM1 or mutants in RCC4 cells and examining cell proliferation (Fig. 2.6D). 
Because of its diminished chromatin binding characteristics, we hypothesized that the BD2/4 
mutant would have the greatest effect on proliferation. Expression of PBRM1 with a BD4 
mutation demonstrated a significantly increased proliferation rate compared with wild-type 
PBRM1. In contrast, expressing the BD2 mutant did not affect proliferation.  PBRM1 harboring 
mutations in both BD2 and 4 resulted in the greatest change in proliferation. Together these 
data suggest that both BD2 and BD4 participate in chromatin interaction. However, phenotypic 
consequences of PBRM1 mutation were only observed in the context of a BD4 mutation.  
 
2.4 Discussion 
To understand the role of PBRM1 as the potential targeting subunit of the PBAF complex, 
we explored the binding specificity of the individual and tandem pairs of BDs and the 
consequence of cancer-associated mutations within these domains. We demonstrate the 
importance of BD2 and BD4 in mediating PBRM1 chromatin interactions. BD2 and BD4 share 
sequence similarities that are reflected in their selective ability to bind modified histone tails. 
Using peptide microarrays and nucleosome pull-downs we found that both BD2 and BD4 
preferentially bound nucleosomes marked by H3K14ac, H3K4me3, and/or H4K16ac. 
Additionally, we demonstrated that neighboring BDs influence BD2 and BD4 binding.  Mutations 
in BD4 observed in ccRCC disrupted PBRM1 nucleosome interactions and enhanced cell 
proliferation.  
Our study highlights the importance of BD4 for PBRM1 function. Although BD2 and BD4 
mediate histone interactions, the ccRCC missense mutation observed in BD2 (I252R) did not 
affect BD2 binding to nucleosomes (data not shown), whereas BD4 mutations (N601K and 
Y580C) abrogated histone interactions. Further, the pocket mutant, N601K, of BD4 (but not 
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BD2) in full-length PBRM1 affected cell proliferation. We hypothesize that the Y580C mutation 
of BD4 would have similar effects on proliferation as that seen with the N601K mutation since 
this mutation is predicted to further disrupt to the binding pocket. These data suggest that while 
BD2 and BD4 can mediate interaction with chromatin, BD4-chromatin interaction plays a unique 
role for PBRM1 function. Remarkably, previous studies using primarily biochemical assays have 
focused only on BD2 as the primary driver of chromatin interactions via H3K14ac (22, 54, 61, 
62). It is possible that the use of intact nucleosomes in our study rather than the oligopeptides 
used in other studies, together with the low affinity of BDs for histone tails, explains this 
difference. In the absence of tethering to a histone octamer, tail peptides may not be suitably 
presented to chromatin binding proteins. The specific importance of BD4 was also supported by 
a recent study in which expression of a PBRM1 mutant lacking both BD1 and BD2 functioned 
similarly to WT PBRM1 to suppress cell proliferation, whereas loss of all 6 BDs showed 
increased cell proliferation (70). Together with our data, these results suggest that, in contrast 
BD2, BD4 may be necessary for PBRM1 function. Studying the six BDs as tandem pairs, we 
identified relationships between the BDs that influenced their ability to engage nucleosomes. 
Individual BDs have low binding affinities for acetylated lysine substrates (25), suggesting that 
multimers of BDs may enhance affinity. Remarkably, we found that three BDs, none of which 
demonstrated nucleosome association individually, exerted variable effects when in the context 
of neighboring BDs. Specifically, BD1 and BD5 act cooperatively with BD2 and BD4, 
respectively, to enhance binding interactions, whereas BD3 decreased binding. It is possible 
that the enhanced chromatin interaction of the BD1-2 and BD4-5 tandem domains with 
chromatin is mediated through interactions with the unmodified H4 tail.  BDs 1-5 demonstrated 
weak interaction with unmodified H4 tails, and BDs1-2 and 4-5, but not the individual BDs, 
weakly bound unmodified recombinant nucleosomes. Protein stabilization through interactions 
with the H4 tail has been shown in the yeast enzyme, Chd1, which requires binding to the H4 
tail for efficient nucleosome remodeling; tetra-acetylation of the tail reduces Chd1 activity (71). 
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Although additional experiments are necessary to establish the interaction with H4, BD1 and 
BD5 could augment nucleosome binding, primarily mediated by BD2 and BD4. In contrast to 
BD1 and BD5, adding BD3 to BD2 or 4 diminished binding. This finding is supported by a recent 
study demonstrating that mutation of the binding pocket of BD3 resulted in a slight, although 
statistically insignificant, enhancement of PBRM1 chromatin association (54). Collectively, these 
data suggest that the PBRM1 BDs offer variable roles to enhance or limit chromatin interaction, 
perhaps resulting in a dynamic interaction across the genome.  
We demonstrate that PBRM1 mutants that disrupt chromatin interaction interfere with 
PBRM1 effects on cell proliferation. This suggests that the BD2 and BD4-mediated chromatin 
interaction is important for the effects of PBRM1 on cell growth. This conclusion is supported by 
a recent study (70) demonstrating that expression of a mutant lacking all six BDs increased cell 
proliferation, whereas expression of a mutant lacking both BD1 and BD2 functioned similarly to 
WT PBRM1 to suppress cell proliferation. Another recent study suggested that PBRM1 plays a 
tumor suppressive role by downregulating expression of genes involved in the cell cycle and 
increasing the number of cells in G1 (72). Together with these studies, our results link PBRM1-
chromatin interaction with regulation of cell proliferation. However, future studies are necessary 
to better understand how PBRM1 targeting alters the transcriptome.  
Since BDs are known to mediate interactions with acetylated histones, we initially 
considered that the H3K4me3 interaction was indirect. Separating these interactions using cell-
derived nucleosomes is challenging because these modifications are both enriched at 
transcriptionally active TSSs (73). However, using recombinant nucleosomes we found that BD2 
and BD4 can weakly bind H3K4me3. Based on NMR structure, we speculate that H3K4me3 
may weakly interact with the BD outside of the acetyl-lysine binding pocket. This observation is 
a source of ongoing investigation in lab. These data suggest that PBRM1 is targeted to 
transcriptionally active regions of the genome marked with H3K14ac and H3K4me3, whereby 
BD2 and BD4 mediate the primary interaction with H3K14ac but may also be stabilized through 
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an interaction with H3K4me3. Like BPTF, PBRM1 could engage in multivalent interactions with 
acetylated and methylated histone tails (15).   
Collectively, these data illustrate the distinctiveness of the six PBRM1 BDs to mediate 
nucleosome interactions and the consequence of ccRCC mutation in the critical domains. We 
highlight the specific importance of BD4 to facilitate these interactions and that mutations within 
this domain enhance cell proliferation, which may promote ccRCC development. In addition to 
limiting cell proliferation, recent studies point to a role of PBRM1 in modulating immune 
responses. For ccRCC patients and in a mouse melanoma model, the absence of PBRM1 
enhances efficacy of immune checkpoint inhibition (74, 75). As BD4 plays an especially 
significant role in chromatin recognition, it may offer an important therapeutic target.  
 
2.5 Methods 
2.5.1 Modeling PBRM1 bromodomains 
Mutations in kidney cancer were identified using cBioPortal on 3/4/18 (Kidney, TCGA, IRC, 
U Tokyo, MSKCC, Genentech, BGI). The protein sequences of the six PBRM1 BDs were 
curated from UniProt (Q86U86). Hierarchical clustering was performed by Unweighted Pair 
Group Method Arithmetic Mean analysis (67) and the tree diagram was generated by JalView 
(76). Sequence alignment was performed using Clustal Omega (77). Homology was determined 
using the percent overlap of the aligned regions.  
 
2.5.2 Preparation and purification of recombinant PBRM1 bromodomains 
DNA containing the coding regions for the single and tandem PBRM1 BDs were PCR-
amplified from cDNA generated from 293-T mRNA and inserted into a pGEX-6P-1 expression 
vector. Mutagenesis of BD4 and BD4-5 was performed with the QuickChange II XL Site-
Directed Mutagenesis kit (Agilent Technologies). All constructs were sequenced to confirm 
accuracy prior to protein purification. Transformed E.coli BL21 cells were grown in Luria-Bertani 
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medium, supplemented with ampicillin (50 µg/mL), and protein expression was induced 
overnight at 18 °C with 0.4 mM IPTG. Cells were harvested by centrifugation, resuspended in 
lysis buffer (1x PBS, 1mM DTT, 1mM PMSF) and sonicated. Insoluble proteins were cleared by 
centrifugation and proteins were purified with GST-agarose (Pierce). Resin was resuspended in 
elution buffer (50 mM Tris, 10 mM glutathione). Proteins were concentrated (Millipore Amicon 
Ultra-15 concentrators) and dialyzed in storage buffer (20 mM Tris pH 8, 150 mM NaCl, 1 mM 
DTT, 10% glycerol). Single BDs correspond to amino acids 31-169 (BD1), 162-348 (BD2), 341-
512 (BD3), 497-661(BD4), 654-784 (BD5), 776-903 (BD6). Tandem BDs correspond to amino 
acids 31-340 (BD1-2), 165-512 (BD2-3), 341-646 (BD3-4), 498-769 (BD4-5), 639-890 (BD5-6). 
Tandem BDs were further purified by FPLC on an AKTAxpress. Samples were examined by 
SDS-PAGE.   
 
2.5.3 Histone peptide microarrays 
Array preparation and protein analysis was performed as described (68, 78). Proteins (1 μM) 
were incubated with peptide microarrays in PBST with 5% BSA overnight at 4 °C. Arrays were 
washed with PBS, incubated with a GST antibody (Sigma) for 2 hours, then washed with PBS 
and finally incubated with an Alexa 647 anti-rabbit antibody (Invitrogen). Arrays were scanned 
(Typhoon Trio+ Imager, GE Healthcare), and the interactions were quantified by fluorescence 
(ImageQuant array software, GE Healthcare). The signal from each of the six spots for each 
peptide were averaged and values were normalized to the highest calculated value across all 
peptides and plotted on a scale from 0 to 1. Heat maps were created using GENE-E and 
represent the mean of two independent arrays.  
 
2.5.4 Mononucleosome preparation 
Nucleosomes were prepared as described (15). Briefly, following a 1 h treatment with 1 µM 
vorinostat, 293-T cells were washed twice with 1x PBS and resuspended (10 mM HEPES pH 
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7.9, 10 mM KCl, 1.5 mM MgCl2, 340 mM sucrose, 10% (v/v) glycerol, 0.5 mM PMSF, 5 mM 2-
mercaptoethanol, 1x Roche protease inhibitor cocktail, 0.5 mg/ml vorinostat). Cells were lysed 
using 0.1% Triton X-100 detergent. Nuclei were separated through a sucrose gradient followed 
by an in nucleo MNase digestion and nucleosome recovery. Cells were digested with 0.25, 0.5, 
1, 2, and 4U of MNase (Worthington) per 70 µg of DNA for 8 minutes. Reactions were stopped 
using 1.3 mM EGTA. Fractions from each treatment were evaluated by agarose gel 
electrophoresis to confirm proper digestion. For further purification and isolation of 
mononucleosomes, samples were applied to a second sucrose cushion and ultracentrifuged for 
17 hr, 27000 rpm in SW40 rotor, 4°C. Fractions were collected and separated by agarose gel 
electrophoresis. Fractions containing only mono-nucleosomes were collected and concentrated 
(Amicon concentrators, Millipore) and brought to 5% glycerol.   
 
2.5.5 Cellular nucleosome pull-downs 
GST nucleosome pull-downs were performed by applying 10 µg of nucleosomes on a 10 μl 
bed volume of 500 pmoles pre-immobilized protein on glutathione agarose (Pierce). 
Nucleosomes and BD bound resin were incubated for 2 hours at 4 °C in 1x PBS, 0.1% NP-40, 
0.5% BSA. Resin was washed with binding buffer. Proteins were eluted using 2x SDS-loading 
buffer and separated on a 4-15% gradient SDS-PAGE (BioRad). Proteins were transferred to a 
nitrocellulose membrane and immunoblotted with antibodies (GST, MA4-004, Thermo; total H3, 
13-0001, Epicypher; H3K9ac, 07-352, Millipore; H3K14ac, ab82501, Abcam; H3K18ac, 39130 
Active Motif; H3K27ac, ab4729, Abcam; H3K4me3, 07-473, Millipore; H3K9me3, ab8898, 
Abcam; H3K27me3, ab6002, Abcam; H4K5ac, ab51997, Abcam; H4K16ac, ab109463 Abcam; 
panH4ac, 05-858, Millipore) followed by anti-mouse and anti-rabbit IRDye secondary antibodies 
(LI-COR Biosciences, Lincoln, NE). Signal was quantified (Odyssey IR imager, LI-COR 
Biosciences), and densitometry analysis was performed (ImageStudio version 2.0). Signal was 
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normalized to GST input and plotted as a fraction of total nucleosome input. At least three 
replicates were performed for each pull-down. 
 
2.5.6 Recombinant nucleosome pull-downs 
Recombinant nucleosome pull-downs were performed by applying 250 pmoles of GST-BD 
on a 10 μl bed volume of 500 pmoles pre-immobilized nucleosomes (H3K4me3, Epicypher 16-
0316; H3K14ac, Epicypher 16-0343; Unmodified, Epicypher 16-0006) on streptavidin magnetic 
beads (Pierce). Nucleosomes and BD bound resin were incubated for 2 hours at 4 °C in 50 mM 
Tris-HCl pH 8.0, 0.1% NP-40, 150 mM NaCl. Beads were washed with binding buffer. Proteins 
were eluted using 2x SDS-loading buffer and separated on a 4-15% gradient SDS-PAGE 
(BioRad). Proteins were transferred to a nitrocellulose membrane and immunoblotted with 
antibodies (GST, MA4-004, Thermo; total H3, 13-0001, Epicypher) followed by anti-mouse/anti-
rabbit IRDye secondary antibodies (LI-COR Biosciences, Lincoln, NE). Pull-downs with different 
NaCl concentrations are indicated individually. For these reactions, the entire pull-down was 
performed in the specified NaCl concentration.  
 
2.5.7 Circular dichroism spectroscopy 
Proteins were diluted to a concentration of 0.5 µg/µL in 20 mM sodium phosphate (pH 7.0), 
150 mM sodium fluoride, and 0.2 mM tris(2-carboxyethyl)phosphine. CD spectra were 
generated using a 0.1-cm quartz cuvette (Chirascan Plus, Applied Photophysics Inc.) Assays 
were conducted at 20 °C from 190 to 260 nm with a step size of 0.5 nm. Background 
absorbance measured using the buffer alone was subtracted from sample spectra. The CD 





2.5.8 Preparation and lentiviral infection of full-length PBRM1 cell lines 
Site-directed mutagenesis was performed on pBabepuro-BAF180 (Addgene plasmid 
#41078) and cloned into tetracycline inducible lentiviral vector TetO-FUW (Addgene plasmid # 
20323) and used in combination with pLenti CMV rtTA3 Hygro (Addgene plasmid # 26730). 
Plasmid sequences were checked by Sanger sequencing. Lentivirus for plasmids were 
produced from transfection of 293T cells with constructs and packaging vectors (pVSVG, pRRE, 
pRSV). Supernatant was collected after 48 hours and concentrated with Lenti-X Concentrator 
(Clontech). RCC4 cells were infected with CMV lentivirus for 48 hours and treated with 
hygromycin (200 µg/mL). After one week of selection, cells were infected with WT and mutant 
TetO constructs. Cells were treated with puromycin (0.6 µg/mL) 48 hours post-infection and 
selected for 1 week. Cells were induced with doxycycline (1 µg/mL) for 72 hours and PBRM1 
expression was assessed by Western blot (Bethyl A301-591A).  
 
2.5.9 Salt fractionations 
 RCC4 cells were treated with doxycycline (1 μg/mL) for 72 hours. Salt fractionations were 
performed as previously described(54). 10 million RCC4 cells were used for each salt 
fractionation. Proteins were transferred to a nitrocellulose membrane and immunoblotted with 
antibodies (GST, MA4-004, Thermo) followed by anti-mouse IRDye secondary antibodies (LI-
COR Biosciences, Lincoln, NE). Experiments were performed in triplicate. Signal was plotted as 
a fraction of total PBRM1 eluted. 
 
2.5.10 Cell proliferation assays 
RCC4 cells (2 x 104) were plated in 6 cm tissue culture dishes on day 0 with 1 μg/ml of 
doxycycline. Cells were trypsinized at day 3, 5, and 7 and counted using a BioRad Tc20 








CHAPTER 3: PBRM1 LOSS ALTERS CHROMATIN ORGANIZATION AT ENHANCERS 
LEADING TO ALTERED GENE EXPRESSION 
 
3.1 Overview 
PBRM1 is mutated in over 40 percent of all clear cell renal cell carcinomas (ccRCCs) and is the 
second most frequently mutated gene behind VHL—a regulator of hypoxia inducible factors 
(HIFs). How PBRM1 loss promotes tumor development is not well understood. We 
hypothesized that PBRM1 loss alters chromatin structure, resulting in critical changes in gene 
expression. To explore changes in chromatin organization associated with PBRM1 loss, we 
performed FAIRE-seq on a cohort of primary ccRCC human tumor samples. We identified 
distinct changes in chromatin accessibility associated with PBRM1 loss. We assessed changes 
in chromatin organization due to PBRM1 loss alone by FAIRE-seq and MNase-seq in RCC cells 
with and without PBRM1. We found that PBRM1 loss leads to altered chromatin organization 
and increased nucleosome fuzziness. Enhancer ChIP demonstrated that PBRM1 is responsible 
for maintaining enhancers. Loss of PBRM1 altered enhancer maintenance. We also performed 
RNA-seq in RCC cells in the presence or absence of PBRM1 and demonstrated that PBRM1 
loss affects expression of a significant number of genes, enriched in metabolic processes. 
Interestingly, loss of PBRM1 led to a gain in enhancers that were enriched for the HIF motif.  
Because of the recognized importance of HIFs in RCC, we explored the influence of PBRM1 
loss on HIF regulated genes. HIF regulated genes were identified by knocking down HIF-1α and 
HIF-2α in isogenic RCC cells followed by RNA-seq.  To test whether PBRM1 loss could alter 
expression of HIF regulated genes, HIF1a and HIF2a were knocked down in the presence or 
absence of PBRM1 in isogenic RCC cells. RNA-seq revealed that HIF regulated genes were 
substantially affected by the presence or absence of PBRM1. Together, this suggests that.
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PBRM1 loss may contribute to tumor progression by affecting transcription mediated by 
alterations in chromatin organization.  
 
3.2 Introduction 
Clear cell renal cell carcinoma (ccRCC) is the main histological subtype of kidney 
cancer, making up over 70 percent of all cases. Until recently, ccRCC was characterized 
predominantly by VHL loss (79–81). VHL regulates hypoxia inducible factors (HIFs) that under 
normal physiological circumstances give cells the ability to respond to changes in oxygen 
conditions by upregulating genes involved in various pathways, including vasculogenesis, 
erythropoiesis, and angiogenesis(82). VHL loss, however, leads to the uncoupling of HIFs from 
oxygen conditions, leading to a permanent pseudohypoxic state(82, 83). Surprisingly, VHL loss 
alone is not sufficient for tumor development (84). Frequent loss of chromatin regulators, 
including PBRM1, SETD2, and BAP1 have since been identified in ccRCC (81, 85). 
Interestingly, the three most frequently mutated genes in ccRCC were all chromatin regulators 
and are all located within a 43 Mb region of chromosome 3p that is frequently lost in ccRCC 
(86). This suggests that chromatin dysregulation plays a significant role in ccRCC progression 
(87–91).  
PBRM1 is the most frequently mutated gene in ccRCC, after VHL(86–89). PBRM1 is a 
unique member of the PBAF SWI/SNF chromatin remodeling complex that is responsible for 
restructuring chromatin through the sliding and/or ejection of nucleosomes (92). Studies have 
demonstrated that PBRM1 plays a role in cardiac chamber formation(93), cell proliferation(89, 
94) and regulates expression of genes involved in metabolism and cell adhesion (72). However, 
little, remains known about how PBRM1 dysregulates these processes and is functioning as a 
tumor suppressor.  
Because PBRM1 is part of a chromatin remodeling complex, we hypothesize that its loss 
contributes to oncogenesis through altered chromatin organization. However, how PBRM1 loss 
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affects chromatin organization has yet to be elucidated. A recent study identified the role of the 
SWI/SNF BAF complex at enhancers, demonstrating that the BAF complex helped to establish 
and regulate the enhancer landscape (95). PBRM1 is thought to be the targeting subunit of the 
PBAF complex due to the presence of multiple bromodomains (54, 89, 96). Therefore, loss of 
PBRM1 may result in the destabilization of enhancers. Additionally, in 40 percent of ccRCCs 
there is the loss of PBRM1 and upregulation of HIFs due to the loss of VHL. Previous studies 
have linked PBRM1 loss to the amplification of the HIF signature (70), however, the mechanism 
was unclear. We hypothesize that PBRM1 is functioning as a tumor suppressor by altering 
chromatin organization and deregulating enhancers.  
In this study, we assessed the genome-wide effect of PBRM1 on chromatin organization 
by FAIRE-seq and MNase-seq.  Because the SWI/SNF complex has been implicated at 
enhancers, we also assessed the effect of PBRM1 loss on the formation of enhancers. Lastly, 
we examined transcriptional changes associated with PBRM1 loss. We found that PBRM1 has 
a dual function, acting to both open and close chromatin. We demonstrate that with loss of 
PBRM1, conserved nucleosomes shift and become less conserved. PBRM1 led to altered 
enhancer formation showing both a gain and loss of enhancers. Shifted enhancers were 
associated with gene that showed changes in gene expression after PBRM1 loss. Together 
these data lay the foundation for understanding the role of PBRM1 on chromatin organization 
and a mechanism for how its loss affects gene expression.  
 
3.3 Results  
3.3.1 ccRCC tumors with PBRM1 loss show enrichment for open chromatin   
A fundamental component of ccRCC is the allelic loss of chromosome 3p. Mutation of 
any gene on the other 3p copy results in biallelic loss, as commonly seen with VHL loss in 
ccRCC. We first determined whether select genes on the 3p arm were more likely than others to 
show biallelic loss. To do this, we collected all TCGA ccRCC data and determined the mutation 
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frequency of each gene along the 3p arm (Figure 3.1A). Only select genes were significantly 
mutated, including BAP1, SETD2, PBRM1 and VHL. In agreement with others, PBRM1 and 
VHL were the most frequently mutated in ccRCC, suggesting that PBRM1 does play a 
significant role in ccRCC.   
We next examined the chromatin organization of ccRCC tumors with and without 
PBRM1 by FAIRE-seq (Figure 3.1B). Regions with differential FAIRE signal separated into two 
groups. Cluster 1 was enriched for regions that were nucleosome depleted in the presence of 
PBRM1 but were closed in ccRCC tumors that had loss of PBRM1. Cluster 2 was enriched for 
regions that were nucleosome depleted only in the absence of PBRM1. These data 
demonstrated that ccRCC tumors exhibiting PBRM1 loss were more nucleosome depleted than 
those that had PBRM1, suggesting that PBRM1 may play a role in maintaining closed 
chromatin. In tumors with PBRM1 loss, regions that became nucleosome depleted were 




Figure 3.1: ccRCC tumors with PBRM1 loss show increased chromatin accessibility. A) 
Frequency of mutations in TCGA ccRCC tumors on chromosome 3. B) Heatmap of FAIRE-seq 
signal under 500bp windows of primary ccRCC tumors. C) Barplot of the percent of regions 
found in intergenic space for Cluster 1 and Cluster 2 as compared to the percent of the genome 
that is intergenic.  
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3.3.2 FAIRE-seq on isogenic PBRM1 knockdown cells shows altered chromatin 
organization    
Because tumors are inherently complex, exhibiting complex mutational profiles, we 
wanted to examine the chromatin changes specifically associated with PBRM1 loss. We 
knocked down PBRM1 in a ccRCC cell line, UMRC2. Because PBRM1 is part of the PBAF 
complex, we wanted to ensure that chromatin changes were associated with loss of PBRM1 not 
the entire complex. Therefore, we assessed protein levels of various PBAF subunits by Western 
blot (Figure 3.2A). Loss of PBRM1 did not alter the levels of PBAF subunits examined.  
To examine changes in chromatin organization associated with PBRM1 loss, we 
performed FAIRE-seq on the UMRC2 cells with and without PBRM1. Loss of PBRM1 altered 
chromatin organization, showing both a loss of nucleosome depleted regions (21124 regions 
closing with PBRM1 loss) and a gain of nucleosome depleted regions (34135 regions opening 
with PBRM1 loss) (Figure 3.2B). This suggested that PBRM1 has a duel function by both 
helping to maintain closed and open chromatin. We next examined whether specific genomic 
features were affected by the loss of PBRM1 by examining the genomic features enriched in 
regions lost, shared, or gained with PBRM1 loss (Figure 3.2C). Regions that close with PBRM1 
loss (shNS unique) were enriched for distal intergenic regions. This suggests that distal 
intergenic regions that are normally maintained in an open chromatin status are now closing in 
the absence of PBRM1. Regions that were open regardless of PBRM1 status (shared) were 















Figure 3.2: PBRM1 loss in isogenic cell line shows altered chromatin accessibility by 
FAIRE-seq. A) Western blot analysis of SWI/SNF subunits in UMRC2 cells after PBRM1 
knockdown. B) Venn diagram of unique and shared regions identified by FAIRE-seq after 
PBRM1 knockdown. C) CEAS analysis identifying genomic features enriched in shared and 
unique regions of open chromatin after PBRM1 knockdown. 
 
3.3.3 PBRM1 loss alters nucleosome positioning away from promoters 
Since PBRM1 is part of a chromatin remodeling complex, we hypothesized that PBRM1 
was altering chromatin architecture through the repositioning of nucleosomes. To examine 
changes in nucleosome positioning associated with PBRM1 loss, we performed MNase-seq on 
UMRC2 cells with and without PBRM1. To ensure isolation of nucleosomal DNA associated with 
heterochromatic and euchromatic nucleosomes, cells were treated with various concentrations 
of MNase and DNA (100-200bp) was collected for sequencing (Figure 3.3A). Little changes 
were seen in nucleosome positioning at exons or transcriptional start sites (TSSs) by MNAse 
signal (Figure 3.3B). This supported the ccRCC tumor data (Figure 3.1) that chromatin changes 
were occurring outside of the gene. From both the tumor (Figure 3.1) and cell line (Figure 3.2) 
data, we did not suspect that PBRM1 was functioning genome-wide on every nucleosome. 
Therefore, we next examine changes in individual nucleosome positioning (Figure 3.3C). 
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Nucleosomes that were shared between shNS and shPBRM1 samples (found within the same 
150bp region) were identified. The distance from the peak of each sample (shNS vs shPBRM1) 
was calculated and plotted, illustrating the degree of shifting associated with PBRM1 loss. Three 
other samples (SETD2 Parental vs inactive B7, SETD2 Parental vs inactive E5, and control vs 
shBRG1) were used as controls. SETD2, a histone lysine methyltransferase that has not been 
shown to be associated with nucleosome repositioning, showed little shifting in nucleosome 
positioning, with the majority of shared nucleosomes shifting <50bp. Interestingly, BRG1, the 
ATPase of the PBAF complex, showed nearly identical shifting in nucleosomes as compared to 
loss of PBRM1 alone. This suggests that loss of PBRM1 alone can have similar effects as loss 
of BRG1.  We next assessed the percent of shifted nucleosomes that were next to a promoter 
(<1kb) (Figure 3.3D). While SETD2 shifted nucleosomes were more commonly associated with 
a proximal promoter as compared to the expected genomic average, shifted nucleosomes 
associated with PBRM1 loss or BRG1 loss were de-enriched for promoters, again suggesting 








Figure 3.3: PBRM1 loss increases nucleosome fuzziness by MNase-seq. A) Gel 
electrophoresis of UMRC2 cells treated with increasing amount of MNase in WT and PBRM1 
KD cells B) MNase signal at Exons and TSSs before and after PBRM1 knockdown C) Distance 
between conserved nucleosomes before and after treatment. Red indicates controls (WT vs 
SETD2 KD or WT vs BRG1 KD), while blue indicates WT vs PBRM1 KD. D) Barplot of the 





3.3.4 PBRM1 loss alters enhancer maintenance 
Previous studies have demonstrated the presence of SWI/SNF complexes at enhancers 
(95). Therefore, we next examined the effect of PBRM1 loss on enhancers.  ChIP-seq for marks 
of enhancers (H3K27ac and H3K4me1) was performed on UMRC2 cell with and without 
PBRM1 (Figure 3.4A). Enhancers were defined as regions with both H3K27ac and H3K4me1 
and were identified in at least two of the three replicates (Figure 3.4B). PBRM1 loss resulted in 
altered enhancers (Figure 3.4C). PBRM1 loss led to gained enhancers that were enriched in 
processes involved with hypoxia, including VEGFR signaling, ERK activation and hypoxia 
regulation (Figure 3.4D). Because VHL regulates HIFs, and HIFs are known to be upregulated 
in ccRCC, gaining enhancers over hypoxia regulated genes suggests a link between enhancers 
regulated by PBRM1 and hypoxia regulated genes. Additionally, these enhancers showed a 
strong enrichment for the HIF motif.  
To assess whether altered enhancers were associated with changes in nucleosome 
positioning, we next looked at MNase signal under lost (unique shNS) or gained (unique 
shPBRM1) enhancers after PBRM1 KD (Figure 3.4E). Unique shNS enhancers showed a well-
positioned nucleosome prior to MNase treatment that becomes less well-positioned after 
treatment as demonstrated by a split peak at the center of the enhancer (red). shPBRM1 unique 
enhancers did not show a well-positioned nucleosome at the center of the enhancer prior to 
PBRM1 KD (black), however, after knockdown, new enhancers showed a more well-positioned 
nucleosome. These data demonstrate that the enhancers require a well-positioned nucleosome 
at the center of the enhancer.  
We next examined FAIRE signal under lost and gained enhancers after PBRM1 KD. 
There were little changes in FAIRE signal under lost enhancers, however, gained enhancers 
were more open in the shPBRM1 sample. We next overlapped the genes associated with 
shPBRM1 unique enhancers with genes that showed increased chromatin accessibility in the 
ccRCC tumors that had PBRM1 loss (Figure 3.1B, Cluster 2) (Figure 3.4G). Over half of the 
 48 
genes that showed increased chromatin accessibility in ccRCC tumors with PBRM1 loss (Figure 
3.1B, Cluster 2) overlapped genes were associated with a gained enhancer after PBRM1 loss. 
These data suggest that PBRM1 loss leads to altered enhancers that may be due to altered 
nucleosome positioning.  
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Figure 3.4: PBRM1 loss alters enhancers. A) Genome tracks of H3K27ac and H3K4me1 
ChIP-seq used to identify enhancers. B) ChIP-seq signal of H3K27ac and H3K4me1 under 
called enhancers for shNS and shPBRM1 samples. C) Venn diagram of lost and gained 
enhancers after PBRM1 KD. D) Pathways enriched in gained enhancers after PBRM1 loss. HIF 
motif identified under gained enhancers after PBRM1 loss. E) MNase-seq signal under lost and 
gained enhancers after PBRM1 loss. F) FAIRE-seq signal under lost and gained enhancers 
after PBRM1 loss.   G) Venn diagram of genes associated gained enhancers after PBRM1 loss 
versus genes that showed a gain in chromatin accessibility in ccRCC tumors after PBRM1 loss 
(Figure 3.1B).  
 50 
3.3.5 PBRM1 loss alters gene expression 
We next examined changes in gene expression associated with PBRM1 loss by RNA-
seq. PBRM1 loss resulted in altered gene expression, with more genes (62%) showing a 
decrease in gene expression than an increase (38%) (Figure 3.5A). The downregulated genes 
were associated with metabolic processes, while the upregulated genes were involved in 
vasculature, cardiovascular system, and circulatory system development (Figure 3.5B).  Of the 
genes that showed a change in expression after PBRM1 loss, both up and downregulated 
genes were associated with differential enhancers after PBRM1 loss (Figure 3.5C). Almost forty 
percent of the upregulated genes and twenty-five percent of the downregulated genes were 




Figure 3.5: Transcriptional changes associated with PBRM1 loss by RNA-seq. A) Heatmap 
of RNA-seq signal under differentially expressed genes. Red indicates upregulated, while blue 
indicates downregulated. B) Pathways enriched for upregulated and downregulated genes after 
PBRM1 loss. Purple indicates downregulated pathways, while green indicates upregulated 
pathways. C) Barplot of upregulated and downregulated genes associated with differential 
enhancers after PBRM1 loss. Green indicates the expected overlap by chance.  
  
  
3.3.6 Select HIF target genes require PBRM1 for regulation 
Because altered enhancers associated with PBRM1 loss showed changes in hypoxia 
regulated genes and because HIF dysregulation is common in ccRCC, we next assessed genes 
associated with PBRM1 loss and/or loss of either HIF1 or HIF2 by RNA-seq (Figure 3.6A). To 
assess whether PBRM1 loss can have an effect on HIF regulated genes, we first determined 
whether they shared target genes by overlapped genes upregulated by PBRM1 loss with HIF1 
or HIF2 responsive genes (Figure 3.6B). Thirteen percent of HIF2 target genes and eight 
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percent of HIF1 target genes were also upregulated with PBRM1 loss. Of the 471 genes that 
were upregulated with PBRM1 loss, forty-four percent were HIF regulated genes.  We, 
therefore, next determined how many of the genes regulated by both PBRM1 and HIF 
overlapped genes that were upregulated with PBRM1 loss and showed a gained enhancer 
(Figure 3.6C). Over half of PBRM1 and HIF regulated genes were associated with a gained 
enhancer. Together these data suggest that PBRM1 loss leads to altered enhancers. 
Enhancers that are gained with PBRM1 loss were commonly associated with upregulated genes 







Figure 3.6: PBRM1 and HIFs share target sites by RNA-seq. A) Schematic of PBRM1 and 
HIF KD in UMRC2 cells B) Venn diagram of PBRM1, HIF1, and HIF2 targets defined by RNA-
seq. C) Venn diagram of overlap of PBRM1 and HIF regulated genes with genes that showed a 





To examine the role of PBRM1 on chromatin structure, we took a genome-wide 
approach to examine chromatin changes associated with PBRM1 loss. We demonstrate that 
PBRM1 plays a role in both the opening and closing of chromatin, as PBRM1 loss resulting in 
both a gain and loss of FAIRE signal. We examined changes in nucleosome positioning 
associated with PBRM1 loss and found that PBRM1 loss increases nucleosome fuzziness, 
suggesting that PBRM1 helps to maintain nucleosome positioning. Because SWI/SNF 
complexes have previously been shown to function at enhancers, we assessed enhancer 
formation with and without PBRM1. While the majority of enhancers were unchanged with 
PBRM1 loss, there were gained and lost enhancers, suggesting that PBRM1 plays a role in 
maintaining select enhancers and when lost can promote the formation of new enhancers. 
Genes associated with PBRM1 loss were associated with metabolic pathways and overlapped 
with enhancers that changed in response to PBRM1 loss. Additionally, we found that select 
genes are affected by both PBRM1 and HIF. Select genes normally regulated by HIFs become 
unregulated with the loss of PBRM1, suggesting a potential mechanism for why 40 percent of 
ccRCCs lose PBRM1. Together these data lay the foundation for how PBRM1 may be acting as 
a tumor suppressor by maintaining the chromatin landscape.  
Studies examining the targeting of the individual PBRM1 bromodomains have that 
PBRM1 is targeted to regions marked with H3K14ac and/or H3K4me3—marks of active 
transcription as well as marks of promoters. By FAIRE-seq we demonstrated that PBRM1 loss 
led to an increase in open chromatin at promoters. However, ccRCC tumors without PBRM1 
were enriched for intergenic regions and enhancers were altered due to PBRM1 loss, 
suggesting that PBRM1 is functioning away from promoters and at enhancers. PBRM1 may, 
therefore, be functioning at both promoters and enhancers by forming enhancer-promoter loops. 
PBRM1 may bind the promoter region of genes and through other PBAF subunits, mediate 
interactions with enhancers. Enhancer-promoter interactions have previously been identified in 
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different cell types (97, 98). BRG1, the ATPase of the BAF and PBAF complex, has been shown 
to bind promoters (99). Since PBRM1 is part of the PBAF complex it is likely that PBRM1 
mediates interactions with promoters and alters enhancers through enhancer loops. To fully 
elucidate whether PBRM1 does bind promoters and helps loop enhancers to the promoter 
elements to help regulate gene expression, interactions should be mapped using high-
throughput assays including, 4C, 5C and Hi-C.  
We found that loss of either BRG1 or PBRM1 resulted in increased nucleosome 
fuzziness (Figure 3.3C). Because the loss of PBRM1 alone had an almost identical effect on 
nucleosome fuzziness as loss of the ATPase subunit, BRG1, this highlights the importance of 
PBRM1 in proper nucleosome positioning. In support of our findings, a previous study has 
demonstrated that loss of Brg1 disrupts nucleosome patterning and decreased the overall 
nucleosome occupancy at promoters (99). However, our findings now suggest that disrupting 
the targeting subunit, PBRM1, alone can have similar consequences as loss of the ATPase 
domain. Previous studies have demonstrated that loss of BRG1 deactivates the entire PBAF 
complex by inhibiting the ATPase function (100). We show here that the increased fuzziness we 
see as a result of the loss of BRG1 can be attributed to loss of PBRM1 alone.  
Together our data demonstrate the effect of PBRM1 loss on chromatin and how its loss 
alters enhancer formation. The changes in chromatin organization and enhancer formation 
altered gene expression and influences HIF targeting. These data lay the foundation for better 
understanding how PBRM1 may be influencing the development of cancer.  
 
3.5 Methods 
3.5.1 Clustering of FAIRE-seq for ccRCC Tumors 
FAIRE-seq and data analysis was performed on 42 ccRCC tumors as previously 
described (Simon et al. 2014). Heatmap was generated using read counts under 500-bp sliding 
windows across the genome. Rows were filtered for sufficient sequencing depth (row average > 
 55 
0.25). Groups were compared using one- or two-sided t-tests (P < 0.01), clustered and plotted 
(Saldanha 2004).  
 
3.5.2 Cell Culture and Generation of PBRM1/HIF Knockdown Cell Lines 
UMRC2 cell lines were cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM) 
(Corning) supplemented with 10% FBS. UMRC2 PBRM1 knockdowns were performed using an 
empty pLKO.1-puromycin or pLKO.1-puromycin containing shRNA to human PBRM1.  Cells 
were split to 20% 24 hours prior to infection. UMRC2 cells were transfected with shRNA 
constructs along with packaging vectors (pVSVG, pRRE, pRSV). After 72 hours cells were 
selected with 1µg/µL puromycin for 1 week. HIFs were knockdown using siRNAs.  
 
3.5.3 FAIRE-seq Cell Culture and Sequencing 
FAIRE was performed as previously described (Simon et al. 2012). Briefly, UMRC2 cell 
lines were divided 24 hours prior to chromatin collection. Cells were fixed with 1% formaldehyde 
for 7 minutes and quenched with 125mM Glycine. Chromatin was collected and sonicated to 
fragment size of <300bp. Nucleosome-depleted chromatin was isolated by phenol-chloroform 
extraction. Chromatin was ethanol precipitated at -80C and collected in 10mM Tris-HCl (pH 7.4). 
Two replicates were performed.  
Sequencing libraries were generated from DNA enriched by FAIRE following the 
manufacturer’s specification for the Tru-Seq library preparation kit (Illumina). Following library 
generation, single end sequencing was performed using Illumina HiSeq2000 (UNC Chapel Hill 
High Throughput Sequencing Facility). Single end 50-bp reads were filtered using TagDust 
(101) and aligned to hg19 using Bowtie (102). Bedtools was used to identify distinct and shared 




3.5.4 Nuclear Extraction and MNase Digestion 
Nuclear extracts and MNase digestion were performed as described (103). Briefly, 
UMRC2 cell lines were split 24 hours prior to cell collection. Cells were harvested at 80% 
confluence and lysed using 1% NP-40. Nuclei were collected and diluted to an OD260 of 0.2. 
Nuclei were treated with a range of MNase U to isolate primarily mononucleosomes.   MNase 
was inactivated with the addition of 10 mmol/L EDTA and ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA). Samples were then treated with RNase A 
and Proteinase K followed by DNA isolation by phenol-chloroform extraction and ethanol 
precipitation. DNA was resuspended in Tris-HCl (pH 7.4) and run on a 2% agarose gel to 
separate nucleosomes. The mononucleosome band (100-200bp) was cut and gel purified 
Qiagen Gel Extraction Kit (Qiagen). 
 
3.5.5 MNase-seq Analyses 
Sequencing libraries were generated from DNA enriched by MNase treatment following 
the manufacturer’s specification for the Tru-Seq library preparation kit (Illumina). Following 
library generation, single end sequencing was performed using Illumina HiSeq2000 (UNC 
Chapel Hill High Throughput Sequencing Facility). Paired end 50-bp reads were filtered using 
TagDust (101) and aligned to hg19 using Bowtie (102). DANPOS was used to analyze 
nucleosome positioning and nucleosome features such as positional ambiguity and occupancy. 
To assess changes in nucleosome positioning, conserved nucleosomes (as identified as being 
in the same 200bp window) were identified and the change in peak positioning was determined 
by assessing the max peak position in both samples.  
 
3.5.6 Enhancer ChIP 
H3K4me1 and H3K27ac ChIP was performed using UMRC2 cells. Cells were harvested 
and fixed for 7 min at room temperature using 1% formaldehyde. Crosslinking was quenched 
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with 125m M glycine for 5 min. Cells were washed two times with cold PBS and homogenized in 
hypotonic solution (10mMTris,pH 7.4, 15mM NaCl, 60mM KCl, 1mM EDTA, 0.1% Nonidet P-40, 
5% sucrose, 1x protease inhibitors). Nuclei were separated by centrifugation through a sucrose 
pad (10 mM Tris, pH 7.4, 15 mM NaCl, 60mMKCl, 10% sucrose, 1x protease inhibitors) and 
resuspended in ChIP buffer (10mM Tris, pH 7.4, 100mM NaCl, 60mMKCl, 1mMEDTA,0.1% 
Nonidet P-40, 1xprotease inhibitors, 0.05% SDS) and sonicated to obtain DNA between 200-
500 bp. DNA was immunoprecipitated with either H3K4me1 or H3K27ac antibody prebound to 
protein A/G beads. Immunoprecipitated complexes were washed with 1x PBS and RNase and 
Proteinase K-treated overnight.   
Sequencing libraries were generated from DNA enriched by ChIP following the 
manufacturer’s specification for the Tru-Seq library preparation kit (Illumina). Following library 
generation, single end sequencing was performed using Illumina HiSeq2000 (UNC Chapel Hill 
High Throughput Sequencing Facility). Single end 50-bp reads were filtered using TagDust 
(101) and aligned to hg19 using Bowtie (102). Peaks were called using MACS2 and bedtools 
was used to identify distinct and shared peaks. Bedtools was used to identify regions of overlap 
between H3K27ac and H3K4me1 that were not also overlapping with RefSeq promoters. 
Enhancers that were not overlapping between treatments and that had both H3K27ac and 
H3K4me1 for at least two of three replicates were identified as differential enhancers. 
Enhancers were associated with genes using the GREAT algorithm. Genes associated with 
differential enhancer regions were analyzed for differential gene expression in an effort to relate 
differential expression to loss or gain of enhancer regions. A permutation test was used to 
determine if differential enhancers were significantly associated with differential genes. Motif 
analysis was performed using HOMER under both constitutive and differential enhancers to 
identify factors that PBRM1 could interact with. GREAT was used to identify pathways that were 
enriched for identified differential enhancers. 
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3.5.7 RNA Isolation and Library Preparation  
RNA was isolated and paired-end sequencing was performed on an Illumina HiSeq 
2000. Two technical replicates were performed. Reads were mapped using Tophat and DESeq 
was used to identify differential genes.  Reads per kilobase per million mapped reads (RPKM) 











CHAPTER 4: HDAC INHIBITORS RESULT IN WIDESPREAD ALTERATION OF THE 
HISTONE ACETYLATION LANDSCAPE AND BRD4 RETARGETING TO GENE BODIES 
 
4.1 Overview 
Histone acetylation is associated with active transcription and serves as a binding site 
for reader proteins that function in transcriptional initiation and elongation. Histone acetylation 
levels are regulated through the actions of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) that antagonistically control the overall balance of this posttranslational 
modification. HDAC inhibitors (HDACi) are potent agents that disrupt this balance and are used 
clinically to treat a range of human diseases including cancer.  Despite their clinical applications, 
little is known about their molecular function. By applying quantitative genomic and proteomic 
approaches, we demonstrate that HDACi robustly increase a low abundance histone acetylation 
state (H4 K5ac/K8ac/12ac/K16ac), which serves as a preferred binding substrate for a variety of 
human bromodomain-containing proteins, including BRD4. This H4 polyacetylation signature 
observed after HDACi treatment accumulates in the transcribed regions of genes and correlates 
with the targeting of BRD4 to genes with increased gene expression. Collectively, these results 
suggest that HDAC inhibition functions, at least in part, through expansion of a rare chromatin 
acetylation state, which then retargets lysine-acetyl reader proteins associated with changes in 
gene expression.  
 
4.2 Introduction 
Acetylation of histone proteins is traditionally associated with active transcription and 
functions to weaken histone-DNA interaction by neutralizing lysine’s positive charge to enhance 
chromatin accessibility (104). In addition, affecting chromatin accessibility, histone acetylation 
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serves as a target of lysine acetyl-containing reader proteins or complexes that carry out a wide 
variety of cellular functions. The bromodomain and extra-terminal (BET) family, which includes 
BRD2, BRD3 and BRD4, is an example of a class of acetyl reader-containing proteins that couple 
acetylation to transcription (31, 32, 105). Whereas the bromodomains in these proteins mediate 
interactions with lysine acetylation, the extra-terminal domain recruits various complexes that can 
regulate transcription.  Specifically, BRD4 scaffolds the positive elongation factor b (P-TEFb) 
complex to chromatin and promotes transcription elongation at sites of histone acetylation (31, 
32, 106). 
Histone acetylation is regulated by two opposing enzyme classes: histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). The dynamic and reversible 
nature of acetylation makes it an ideal therapeutic target. To that end, there has been a 
longstanding interest in the development of HDAC inhibitors (HDACi), and several inhibitors have 
been approved by the Food and Drug Administration (FDA) for oncological indications (107). 
HDACi have varying degrees of specificity for 18 human HDACs, which are classified into Class 
I (HDAC1, 2, 3, and 8), Class IIA (HDAC4, 5, 7, and 9), Class IIB (HDAC6, 10) and Class IV 
(HDAC11) (108). HDACi exhibit anti-proliferative effects in several cancer cell lines (109, 110) 
and mouse models (111). Although HDACi are used clinically, little is known about their mode of 
action. A better understanding of their mechanism may offer insights towards targeted 
applications. 
HDACi treatment rapidly increases global histone acetylation, which is associated with 
both up- and down-regulation of gene expression (112). The overall mechanism of HDACi-
mediated gene regulation and the way in which specific subsets of genes are affected by HDACi 
remain poorly understood. Recent work suggests that HDACi interfere with transcription 
elongation of highly expressed genes in cancer cells (113). In some cells, HDACi decreases MYC 
expression and alters the regulation of MYC target genes (114).  
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Similar to HDACi, bromodomain inhibition by small molecules such as JQ1 leads to 
changes in the expression of MYC and MYC target genes (115, 116). HDACi and BRD4 inhibitors 
have similar anti-tumorigenic effects, and treatment with both HDACi and a BET inhibitor has a 
synergistic effect on tumor cell viability and xenografted mouse survival (117). These similar 
effects seem unexpected based on the mechanisms through which these inhibitors work: HDACi 
should increase BRD4 binding, whereas BET inhibitors prevent BRD4-chromatin interaction. It is 
possible that alteration in the acetyl landscape by HDACi may impact the targeting of BET proteins 
to elicit the observed changes in gene expression. Indeed, HDACi reduce the mobility of BRD4 
on chromatin due to increase bromodomain-acetyl interaction (55).We hypothesized that HDACi 
disrupt the function of BRD4 and other BET proteins on chromatin, possibly through retargeting 
these proteins. Although previous studies have assessed the effect of HDACi on the acetyl 
landscape (118, 119), and the effect of BRD4 inhibition (120), these studies have yet to integrate 
quantitative assessment of acetylation changes in response to HDACi with changes in the 
targeting of acetyl binding proteins.  
We investigated the proteomic and genomic consequences of treatment with the drug 
subaroylanilide hydroxamic acid (SAHA or Vorinostat) on H4 as well as its effect on BRD4 
targeting.  We find that HDAC inhibition results in a robust hyperacetylation of H4 at lysines 5, 8, 
12 and 16, associated with altered transcription. SAHA both enhanced and diminished 
transcription of select genes, suggesting that HDACs have opposing effects and are not 
functioning similarly genome-wide. SAHA preferentially enhances histone acetylation within 
gene bodies and this increased H4 acetylation is associated with BRD4 binding to gene bodies. 
The absence of an effect on BRD4 levels in the context of a massive gain in BRD4 sites 






4.3.1 HDAC inhibition results in H4 polyacetylation  
We performed mass spectrometry on histone proteins from HeLa cells with or without 
treatment with sodium butyrate, a class I/II HDAC inhibitor (20) (Figure 4.1A). In the absence of 
HDACi, the majority of H4 histones are un- or mono-acetylated (89%). However, following 
HDACi histones become hyperacetylated, with over 65% exhibiting H4 di-, tri-, or tetra-
acetylation. To identify whether specific histone PTMs were more preferentially affected by 
HDACi, we quantified the abundance of the H4 acetyl states before and after butyrate treatment 
(Figure 4.1B). The abundance of mono-acetylated histones decreased, regardless of histone 
post-translational modification, while the abundance of di-, tri- or tetra-acetylated histones 
increased. Histones with the higher degrees of acetylation showed the greatest increase after 
butyrate treatment, with tetra-acetylated H4 histones accounting for 20% of histone H4 peptides 
following HDAC inhibition. We also assessed changes in the acetyl state of the H3 tail after 
butyrate treatment. Here, unlike H4ac, mono-acetylated and di-acetylated H3 histones peptides 
were increased (Figure 4.1C, Appendix B Supplementary Figures B.1A-D). Overall, HDACi 





FIGURE 4.1: Sodium butyrate leads to H4 hyperacetylation. A) Pie chart summarizing mass 
spectrometry analysis of H4 peptide acetyl states (un-, mono-, di-, tri-, or tetra- acetyl) identified 
in HeLa cells treated with vehicle or Sodium Butyrate B) Bar graph depicting percent of 







4.3.2 H4 polyacetylation binds transcriptional machinery and BET proteins 
Because HDAC inhibition robustly increased H4 poly-acetylation, we sought to identify 
those reader proteins that favor binding to tetra-acetylated H4. Using unmodified H4 or H4 tetra-
acetylated peptide we performed pulldowns using HeLa nuclear extracts. Isolated proteins were 
assessed by mass spectrometry (Figure 4.2A). Proteins that demonstrated the greatest 
enrichment for H4 tetra-acetylated peptide binding included the BET family members BRD2, 
BRD3 and BRD4. Members of the histone acetyltransferase and the TFIID complex were also 
enriched (Figure 4.2B). To confirm the selective binding of bromodomains from proteins that 
bound the H4 tetra-acetylated peptide, we bound recombinant bromodomains to a peptide 
microarray containing over 250 histone tail peptides with single or multiple posttranslational 
modifications, including mono- or polyacetylated histone tails peptides (Figure 4.2C). 
Bromodomains from BRD2, BRD3 and BRD4, as well as thirteen additional bromodomains, 
were tested. Results from the peptide microarray confirmed that the majority of the tested 
bromodomains favored binding to tri- or tetra-acetyl H4 peptides.  
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FIGURE 4.2: BRD4 recognizes poly-acetylated H4. A) Scatterplot of proteins bound to H4 
unmodified versus H4 tetra-acetylated peptides by peptide pull-down followed by mass 
spectrometry in HeLa cells. B) Complexes enriched for proteins preferentially bound to H4 
tetraacetylated peptides determine by GO analysis. C) Peptide microarrays of select H3 and H4 
acetyl peptides to the indicated bromodomains (BD, bromodomain). 
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4.3.3 Short HDACi treatment minimizes off-target effects 
We next explored the genome-wide effect of a clinically relevant pan HDACi, SAHA, on 
the well-characterized human promyelocytic leukemia cell line (HL60).  Since MYC levels are 
known to be affected by HDACi (121, 122) and MYC can affect chromatin status (123), we 
explored the timing of MYC alterations relative to histone PTM changes to minimize secondary 
effects. H3 and H4 acetylation was increased at 0.5 hours, which preceded decreased MYC 
protein levels at 2 hours (Figure 4.3A). While MYC transcript levels began to diminish at one 
hour, the expression of the MYC target gene, CDKN1A (124), was not affected until 2 hours 
after treatment (Figure 4.3B). From these data, we established 1-hour of SAHA treatment as an 
appropriate interval to measure direct chromatin changes.  
 
FIGURE 4.3: c-Myc-independent transcriptional changes occur at 1 hour after SAHA 
treatment. HL60 cells treated with SAHA for 0, 0.5, 1,2 or 6 hours were assessed by A) 
immunoblot for c-MYC and H3 and H4 acetylation and B) quantitative PCR for c-MYC and 





4.3.4 HDAC inhibition leads to increased H4 polyacetylation of gene bodies 
We next determined the effect of HDAC inhibition on histone H4 acetylation genome-wide 
using quantitative chromatin immunoprecipitation. We focused on H4 polyacetylation because it 
was robustly affected by HDAC inhibition and was a target for bromodomains across many 
proteins. We performed quantitative ChIP-seq (ChIP-Rx) (125), which incorporates Drosophila 
chromatin throughout sample processing to serve as an internal reference (Appendix B, 
Supplementary Figure B.2A). Preferential binding of the antibody to polyacetylated H4 was 
demonstrated by peptide array analysis (Appendix B, Supplementary Figure B.2B). The antibody 
used for ChIP favored di- through tetra-acetyl H4.  Following treatment of HL60 cells with SAHA, 
we observed a striking increase in histone acetylation. The signal increase associated with HDACi 
was not appreciated in the absence of spike-in normalization (Figure 4.4A-B). The massive 
increase in H4 acetylation genome-wide was characterized by a broader distribution of H4 
acetylation around TSSs (Figure 4.4B).  The degree of polyacetylation varied across the genome, 
with a 4- to 8-fold increase in acetylation at most regions (Figure 4.4C). Select regions, however, 
demonstrated little change in acetylation (< 4-fold change), whereas others showed up to a 60-
fold change after treatment.  
We then localized genomic intervals based on the relative variation in acetylation following 
SAHA treatment as well as the absolute signal change. Overlapping 300 bp windows that 
demonstrated differential signal between control and SAHA treatment were merged and divided 
into five classes based on relative signal variation (Figure 4.4D, Appendix B, Supplementary 
Figure B.2C). Regions of the genome that exhibited low levels of H4 acetylation prior to SAHA 
treatment were then divided into two groups: those regions with less than (Quad 1) or greater 
than (Quad 2) median (2.38) fold change after SAHA treatment. The absolute change in acetyl 
signal was minimal for Quad 1, but more pronounced for Quad 2 regions. This suggests that 
regions with low levels of H4ac can be variably affected by histone acetylation, with some regions 
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showing limited changes (Quad 1) and others showing more pronounced H4ac changes (Quad 
2). 
Genomic intervals with greater than median (9.37) levels of H4 acetylation prior to SAHA 
treatment were also divided into two classes based on the relative magnitude of acetylation 
change: those regions with less than (Quad 3) or greater than (Quad 2) median (2.38) fold change.  
Here, regions that showed a high fold change in H4 acetylation levels after SAHA treatment (Quad 
4) also showed a large change in the absolute H4 acetylation levels, suggesting that these regions 
are targets of HATs and are maintained in a hypoacetylated state by ongoing HDAC activity. A 
fifth class was identified (Tail). These regions exhibited the greatest H4 acetylation at baseline 
with a limited relative increase following SAHA treatment (Appendix B, Supplementary Figure 
B.2D). These regions are likely sites of robust HAT activity but with limited HDAC activity. 
We then assessed the enrichment of genomic features in these classes (126) (Figure 
4.4E).  Compared with the overall distribution of these features genome-wide, regions of low 
acetylation that were least affected by SAHA (Quad 1) were enriched for distal intergenic regions. 
In contrast, regions most affected by SAHA (Quad 4) were genic. Regions with very high 
acetylation that showed little fold change but significant change in the absolute H4ac signal (Tail) 
were enriched for promoters. This suggested that highly acetylated regions may be at near 
maximal levels reflected in the small fold change. These data suggest that, while HATs are active 
at both promoters and gene bodies, HDAC activity potently restricts gene body acetylation. We 
next examined H4ac signal in those genes that demonstrated increased H4ac within the gene 
body (Figure 4.4F,G). Increased acetylation preferentially extended into the gene.  
 
HDAC inhibition led to widespread changes in H4 acetylation, with long stretches of DNA 
becoming hyperacetylated. Because super-enhancers are commonly defined as large stretches 
of DNA that exhibit different histone PTMs, including H3K27ac, we next examined changes in 
called super-enhancers. We defined super-enhancers using the standard ROSE algorithms, 
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using H4ac signal. Enhancers were identified by H4ac signal, while super-enhancers were 
identified by the merging of any enhancer within 12.5kb. Enhancers are commonly identified by 
the presence of H3K27ac. We showed that H3K27ac tracks closely with H4ac signal (Appendix 
B, Supplementary Figure B.2E), however, we also compared super-enhancers identified with 
H3K27ac signal to H4ac called super-enhancers (Appendix B, Supplementary Figure B.2F). Over 
sixty percent of super-enhancers overlapped for SAHA unique super-enhancers and 
DMSO/SAHA shared super-enhancers. DMSO unique super-enhancers showed little correlation 
between H3K27ac and H4ac identified super-enhancers, suggesting these are likely false positive 
super-enhancers. We found that SAHA treatment doubled the number of SEs identified (Figure 
4.4H). Interestingly, when we look at changes in transcription associated with SAHA treatment, 
very few genes show any transcriptional changes, demonstrating that alteration of acetylation in 
large regions defined as super-enhancers is not sufficient for altered gene expression.  
 Together these data suggest that SAHA does not uniformly influence acetylation genome-
wide. Rather, HDACi preferentially affect regions with pre-existing H4 acetylation, specifically in 
gene bodies. In addition, HDACi may have widespread consequences by altering the enhancer 





FIGURE 4.4: SAHA leads to increased acetylation in gene bodies in HL60 cells. Figure 4. 
SAHA leads to increased acetylation in gene bodies in HL60 cells. A) Representative 
genome tracks for H4ac ChIP-RX in HL60 cells. B) H4acetyl signal at TSSs with DMSO or SAHA 
treatment (n=2). C) Histogram of log2 fold change between H4ac signal in SAHA and DMSO 
treatments in windows with differential H4ac signal. D) Density plot showing the log2 fold change 
of H4ac signal after SAHA treatment versus signal in DMSO sample in differential windows. Plot 
is divided into 5 sections based on fold change and signal in DMSO treatment.  Bar chart 
demonstrates the magnitude of acetyl changes (SAHA-DMSO) over the window size after SAHA 
treatment within the five groups. E) CEAS analysis identifying genomic features enriched in 
regions with greatest acetyl change. F) Metaplot of H4ac signal in genes enriched for H4ac signal 
in gene body in Quad 4 category. G) Representative genome track demonstrating enriched H4ac 
signal in gene body after SAHA treatment. H) Venn diagram illustrates shared and unique super-
enhancers called using H4ac signal in DMSO and SAHA treatments.  
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4.3.5 HDAC inhibition enhances BRD4 targeting to the bodies of upregulated genes 
We then asked how HDAC inhibition and resulting histone polyacetylation would affect 
bromodomain-containing protein targeting. We focused on BRD4 as it strongly recognized H4 
polyacetylation (Figures 4.2A and 4.2D) and has been implicated in many cancers. We performed 
BRD4 ChIP-seq in HL60 chromatin with or without SAHA treatment (Figure 4.5A). We observed 
changes in BRD4 targeting following SAHA treatment, although signal around TSSs were largely 
unchanged (Figure 4.5B). Although a small number of sites were lost following treatment, SAHA 
doubled the number of BRD4 binding sites (Figure 4.5C). To assess the magnitude of BRD4 
binding we next quantified the amount of BRD4 bound at shared sites in DMSO and SAHA treated 
samples. Because BRD4 protein levels were unaffected by SAHA treatment (Appendix B, 
Supplementary Figure B.3), we hypothesized that the additional BRD4 binding after SAHA 
treatment reflected a decrease in BRD4 levels at preexisting sites. To test this, we compared the 
reads at BRD4 sites that were present in both control and SAHA treated cells (Figure 4.5D). We 
found that for those peaks with differential BRD4 signal, the majority demonstrated a decrease in 
reads following SAHA treatment (212 out of 222). These data suggest that the increased number 
of BRD4 binding sites results from the redistribution of BRD4. The absence of signal variation 
between DMSO and SAHA treatment at the vast majority of BRD4 sites argues against the 
possibility that this difference reflects a dilution of overall read counts. We then characterized the 
genomic features in BRD4 binding sites (Figure 4.5E). Similar to that observed for H4 acetylation, 
BRD4 binding sites gained with SAHA treatment were enriched at gene bodies and de-enriched 
for promoters.  
To explore whether the BRD4 location was functionally associated with transcription, we 
asked if hyperacetylation and BRD4 retargeting by HDAC inhibition correlated with gene 
expression changes. RNA-seq was performed on HL60 cells with and without SAHA for 1 or 2 
hours with spike-in normalization. Genes with changes in RNA abundance at 1 or 2 hours of 
SAHA treatment were highly correlated (by RPKM) (Pearson correlation, 0.972) (Appendix B, 
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Supplementary Figure B.4A). After 2 hours of SAHA treatment, 390 genes demonstrated altered 
mRNA levels (Appendix B, Supplementary Figure B.4B). Of these, 57% (223 genes) were 
upregulated and 43% (167 genes) were downregulated. Downregulated genes included the 
oncogenes (MYC and MYB).  Upregulated genes were not enriched for specific cellular pathways; 
however, downregulated genes were significantly enriched for those gene involved in regulation 
of metabolic processes (Appendix B, Supplementary Figure B.4C). 91 percent of genes 
associated with new BRD4 binding sites were upregulated in response to SAHA (Figure 4.5F). In 
contrast, over 65 percent of genes associated with decreased or unchanged BRD4 binding were 
downregulated in response to SAHA. Together these data suggest that HDACi increases the 
number of BRD4 binding sites. However, this results from BRD4 redistribution. New BRD4 target 





FIGURE 4.5: SAHA leads to new BRD4 binding sites enriched in gene bodies. A) 
Representative genomic tracks for BRD4 ChIP-seq in HL60 cells with shared (green) and 
unique (blue) peaks. B) BRD4 signal at TSSs +/-3kb. C) Venn diagram of unique and shared 
BRD4 peaks identified by ChIP-seq after SAHA treatment. D) Scatterplot demonstrating the fold 
change in the number of reads per shared BRD4 peak. Red signifies p<0.05.  E) CEAS analysis 
identifying genomic features enriched in shared and unique BRD4 binding sites. F) Bar chart 
showing the number of genes upregulated or downregulated for genes associated with BRD4 
binding in DMSO unique, shared, and SAHA unique binding sites. 
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4.3.6 Gained BRD4 binding sites are enriched for H4 acetylation in introns with genes 
exhibiting increased transcription 
 
We then asked whether genes with increased BRD4 signal in gene bodies after SAHA 
treatment also demonstrated increased H4 polyacetylation. We compared the genes with 
increased BRD4 in the gene body after SAHA treatment (BRD4 SAHA Unique, Figure 4.5C) with 
the genes associated with H4ac in the gene body after treatment (Quad 4 windows, Figure 4.4D) 
(Figure 4.6A). Genes with increased BRD4 signal in the gene body were enriched for H4 
polyacetylation in the gene body (88%, p = 0 for random permuted control) (Figure 4.6B). Signal 
distribution at the shared genes (Figure 4.6A) illustrated increased H4ac and BRD4 signal within 
the gene body after SAHA treatment (Figure 4.6C). Greater than 90% of these genes showed 
increased expression (Figure 4.6D). Together these data suggest that treatment with an HDACi 
increases the number of BRD4 binding sites within the gene body through increased H4 
polyacetylation. Genes associated with elevated BRD4 and H4ac signal within the gene body are 
upregulated in expression in response to HDACi.   
Poly-acetylated H4 appears to be sufficient for the assembly of transcriptional machinery, 
including members of the pre-initiation complex (TFIID and TBP) and members that facilitate 
elongation (BRD4 and P-TEFb) (as determined by peptide pulldowns followed by mass 
spectrometry in Figure 4.2). Altered acetylation due to HDACi may, therefore, have considerable 
potential to dysregulate transcription via altered targeting of the transcriptional machinery (Figure 
4.6E). We suggest a model, where actively transcribed genes have high levels of H4ac at 
promoters and low levels of acetylation within gene bodies, which is maintained by HDACs. Under 
normal conditions members of the pre-initiation complex bind to poly-acetylated promoters, 
fostering normal transcription. HDAC inhibition, however, leads to elevated H4ac preferentially 
within gene bodies of these actively transcribed genes, leading to the recruitment of factors, 




FIGURE 4.6: BRD4 is targeted to regions of hyperacetylation in gene bodies and is 
associated with upregulated  gene expression. A) Venn diagram shows overlap of genes 
with increased H4 acetylation in gene bodies versus increased BRD4 signal in gene bodies B) 
Permutation analysis demonstrating the fraction of BRD5 genes overlapping HC genes as 
compared to random regions. C) Representative genomic tracks for a gene exhibiting increased 
H4ac and BRD4 in gene body after SAHA treatment.  D) Bar chart of number of genes 
upregulated or downregulated in genes showing increased H4ac and BRD4 in gene bodies. E) 
Schematic representation of the transcriptional machinery proteins pulled down by H4 tetra-
acetylation and identified by mass spectrometry. 
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4.4 Discussion 
 As readers of histone acetylation, bromodomain-containing proteins play a critical role in 
linking histone acetylation with transcription. Although HDACi globally increase histone 
acetylation and broadly alter gene expression, the precise effects of these compounds on 
histone acetylation and bromodomain targeting have not been quantitatively examined at a 
genome-wide level. The two HDACi used in this study, SAHA and NaBut, similarly inhibit Class I 
and Class IIA HDACs, with SAHA exhibiting additional inhibition of Class IIB HDACs. Using a 
combined proteomic and genomic approach, we demonstrate that polyacetylated histone H4, a 
preferred target for BRD4 and other bromodomains, is greatly increased by Class I and Class II 
HDACi at specific genomic locations, particularly in the bodies of upregulated genes and that 
BRD4 is retargeted to these regions.  
We demonstrate that changes in acetylation in response to HDAC inhibition vary 
genome-wide and are dependent on the acetylation state under normal conditions (Figure 4.4C-
E). The most robust change in H4ac in response to SAHA was observed in the gene body 
(Figure 4.4D). Regions with very high levels of acetylation under normal conditions (enriched for 
promoters) seem to be near maximal acetyl levels, as they showed only minimal relative change 
after HDACi (Figure 4.4D-E, tail). We propose a model, therefore, where HDAC activity is more 
robust in transcribed regions, given the largest changes in histone acetylation are found in these 
regions. Further, promoters showed high levels of acetylation before and after HDACi 
suggesting that HDACs are less active at these locations. Notably, our findings agree with 
others that show HDACs and HATs function antagonistically to control histone acetylation states 
within a. Previous studies have demonstrated that various HATs and HDACs localize to different 
genomic regions. Specifically, HDAC1 and HDAC3 localize to promoters, while HDAC2 and 
HDAC6 bind promoters and gene bodies of active genes (127, 128). HATs have also been 
shown to most prominently localize to promoters but also within the gene body (127). Tip60, a 
member of the MYST family of HATs, is found at high levels at the promoter region but was also 
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detected in active genes(127). Therefore, a balance exists between HATs and HDACs at 
promoters and gene bodies to properly regulate gene transcription.  
BRD4 targeting in gene bodies reflected that of H4 acetylation. After SAHA treatment 
nearly all genes with increased H4ac within the gene body also exhibited elevated BRD4 signal 
at these sites. These genes were associated with elevated gene expression in response to 
SAHA (Figure 4.5). It is likely that BRD4 associates with genes that are actively transcribed and 
that these genes are targets for HDAC activity. However, it is possible that BRD4 binding 
enhances transcription. In support of this model, it has been shown that HDACs bind promoters 
and/or gene bodies of actively transcribed genes (127). A previous study demonstrated that 
BRD4 can function as a HAT to acetylate both H3 and H4 residues. Importantly, they 
demonstrated that BRD4 acetylates H3K122 — a mark crucial for nucleosome stability (129). 
Therefore, increased BRD4 within the gene body may help to further acetylate the gene body 
and decompact chromatin, thereby facilitating the disruption of nucleosomes by Pol II. 
Additionally, because BRD4 protein levels do not change in response to HDACi (Appendix B, 
Supplementary Figure B.3), but the number of binding sites doubles, the amount of BRD4 
present at binding sites is likely diminished (Figure 4.5D). In support of this concept, increased 
chromatin acetylation decreased BRD4 mobility (55). Taken together, these data suggest that 
increased BRD4 within the gene body may act as a sink to decrease the BRD4 at promoters or 
regulatory regions. A previous study has demonstrated that the amount of BRD4 on chromatin 
is associated with the level of transcription — the less BRD4 bound, the less transcription (130). 
Together our data suggest that BRD4 relocates to the bodies of actively transcribed genes, 
thereby diminishing BRD4 available to bind promoter and enhancers. Although seemingly 
contradictory that HDACi and BET inhibitors elicit similar cellular effects, we suggest that the 
two inhibitors actually function similarly to decrease the binding capacity of BRD4, bromodomain 
inhibitors through inhibition of chromatin interaction and HDACi by redistributing BRD4 
throughout the genome.  
 78 
Changes in H4 acetylation likely play a critical role in mediating the effects of HDACi.  
Both BRD4 bromodomains have been shown to be associated with H4 tetra-acetylated 
histones, and the spacing of the acetylated residues on the tails contributes to the polyacetyl 
preferences of the domains (131). Acetylation of the H3 tail was similarly increased after HDACi 
treatment; however, most of the bromodomains we tested did not favor binding to 
polyacetylated H3 peptides, which supports an important role for H4 polyacetylation.  
Applying genomic and proteomic approaches, we have uncovered genome-wide effects 
of HDAC inhibitors on the histone acetylome and the consequence of changes in acetylation on 
bromodomain-containing proteins.  
 
4.5 Methods 
4.5.1 Histone Preparation and Mass Spectrometry Analysis  
Extracted histones were chemically derivatized and digested to tryptic peptides to make 
them amenable for bottom up mass spectrometry as described earlier (132). The derivatized 
samples were desalted prior LC-MS analysis using C18 Stage-tips. For mass spectrometry, the 
peptides were separated using a 75 µm ID x 17 cm Reprosil-Pur C18-AQ (3 µm; Dr. Maisch 
GmbH, Germany) nano-column fitted on an EASY-nLC nanoHPLC (Thermo Scientific, San 
Jose, Ca, USA). The HPLC gradient comprising 0-35% solvent B (A = 0.1% formic acid; B = 
95% acetonitrile, 0.1% formic acid) over 40 min and from 34% to 100% solvent B in 7 minutes at 
a flow-rate of 250 nL/min was used. The nano LC was coupled with an Orbitrap Fusion mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) with a spray voltage of 2.3 kV and 
capillary temperature of 275°C. Full scan MS spectrum (m/z 300−1200) was acquired in the 
Orbitrap with a resolution of 60,000 (at 200 m/z) with an AGC target of 5x10e5. By using the 
Top Speed MS/MS option set to 2 sec, the most intense ions above a threshold of 2000 counts 
were selected for fragmentation. Fragmentation was performed with higher-energy collisional 
dissociation (HCD) with normalized collision energy of 29, an AGC target of 1x10e4 and a 
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maximum injection time of 200 msec. MS/MS data were collected in centroid mode in the ion 
trap mass analyzer (normal scan rate). Only charge states 2-4 were included. The dynamic 
exclusion was set at 30 sec. Peak area was extracted from raw files by using our in-house 
software EpiProfile (133). The relative abundance of a given PTM was calculated by dividing its 
intensity by the sum of all modified and unmodified peptides sharing the same sequence, using 
the total area under the extracted ion chromatograms. 
 
4.5.2 Peptide Pulldown and Mass Spectrometry 
Nuclear extracts were prepared from HeLa cells as previously described (134). Peptides 
were immobilized on High Capacity Streptavidin Agarose Resin (Thermo Scientific) and rinsed 
twice with 0.01% NP-40 in PBS. Nuclear extracts were pre-cleared with resin for 45 min at 4°C 
prior to incubation with peptide-conjugated resin for 4 hr at 4°C. After washing four times with 
150 mM KCl and three times with 250 mM KCl, bound proteins were eluted using 50 mM 
glycine, 150 mM NaCl. A fraction of the final elution was resolved by SDS-PAGE and gels were 
stained with SilverQuest Staining Kit (Invitrogen) to confirm pulldowns. The remaining elutions 
were precipitated with 6X ice-cold acetone overnight at -20°C. After centrifugation, the pellet 
was solubilized in 8M urea and 0.1M ammonium bicarbonate.  
 
4.5.3 Western Blot 
HL60 cells were treated with 1 µM SAHA, 500 nM JQ1 or 0.1% DMSO for the indicated 
time points and collected by centrifugation.  After washing once with cold PBS, cells were flash 
frozen and stored at -80ºC. For lysis, cells were resuspended in lysis buffer (10 mM PIPES pH 
7.0, 100 mM NaCl, 3 mM MgCl2, 300 mM sucrose, 0.1% Triton X-100) supplemented with 
protease inhibitors (Roche) and universal nuclease (Thermo Scientific). After 20 min incubation 
on ice, the lysate was centrifuged and quantified by Bradford assay (Bio-Rad). For histone blots, 
1 µg of total protein was resolved on a 12% SDS-PAGE gel and transferred to PVDF 
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membrane. The following antibodies were used to detect histones: total H4 (Abcam ab10158), 
H4 acetyl (Millipore 06-866), H4K16ac (Active Motif 39167), total H3 (Epicypher 13-001), 
H3K14ac (Millipore 03-353 Lot 2387522), and H3K4me3 (Epicypher 13-004). c-Myc and tubulin 
were detected by resolving 20 µg of total protein was resolved on an 8% SDS-PAGE gel and 
blotting with c-Myc (Abcam ab32072) or beta-tubulin (Millipore 05-661) antibodies.  
 
4.5.4 RNA Sequencing and Analysis 
Total RNA was isolated using TRIzol reagent (Invitrogen 5596026) according to manufacturer’s 
protocol. 750ng of DNAse treated total RNA was subjected to rRNA depletion using RiboZero 
Gold (Illumina MRZG12324). rRNA depleted total RNA was fragmented and reverse transcribed 
using SuperScript II (ThermoFisher 18064014). Sequencing libraries were generated using 
Illumina TruSeq Stranded Total RNA Library Prep Kit according to manufacturer’s protocol and 
single-end sequenced on a NextSeq500. Single end 50-bp sequencing reads were aligned to 
hg19 using STAR v2.5.2b (135). Differential genes were identified by DESEQ2 (136) and count 
data was used to generate the MAplot using RStudio. Gene ontology analysis was performed 
using DAVID (137). 
 
4.5.5 RT-qPCR 
For quantitative PCR analysis, 1.5x106 HL60 cells were treated with 1 µM SAHA, 500 
nM JQ1 or 0.1% DMSO for the indicated time points. Cells were collected, washed once with 
cold PBS, and flash frozen. RNA was isolated using a RNeasy Kit (Qiagen). Two micrograms of 
RNA were reverse transcribed using SuperScript III reverse transcriptase (Thermo Fisher) and 
random hexamer primers. cDNA was diluted 1:20 and target genes were amplified using SYBR 
Green Master Mix (Bio-Rad) and the following primers: c-MYC (5’-
CCTGGTGCTCCATGAGGAGAC-3’, 5’-CAGACTCTGACCTTTTGCCAGG-3’), CDKN1A (5’-
AGGTGGACCTGGAGACTCTCAG-3’, 5’-TCCTCTTGGAGAAGATCAGCCG-3’), GAPDH (5’-
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GTCTCCTCTGACTTCAACAGCG-3’, 5’-ACCACCCTGTTGCTGTAGCCAA-3’). Experiments 
were performed in triplicate and data were collected and analyzed using an ABI 7900HT by 
normalizing to GAPDH expression and calculating fold change relative to DMSO samples. 
 
4.5.6 ChIP-Rx  
ChIP-Rx was performed as previously described with minor modifications (125).  
Drosophila S2 cells were cultured to a density of 1x106 cell/mL. Cells were harvested and fixed 
for 10 min at room temperature using 1/10 volume of fresh formaldehyde fixation solution (11% 
formaldehyde, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM HEPES). Crosslinking was 
quenched with 0.125 M glycine for 5 min. Cells were washed two times with cold PBS, flash 
frozen and stored at -80ºC. 
 HL60 cells were cultured to a density of 7x105 cell/mL and treated with 1 µM SAHA or 
0.01% DMSO for 1 hr. After treatment, cells were treated with 1/10 volume of fresh 
formaldehyde fixation solution for 10 minutes at room temperature and quenched for 5 min. 
Cells were washed two times with cold PBS, flash frozen and stored at -80ºC.  
 Chromatin was prepared by resuspending HL60 and S2 cell pellets in parallel in cold 
Lysis Buffer 1 (107 cell/mL; 140 mM NaCl, 50 mM HEPES pH 7.5, 1 mM EDTA, 10% glycerol, 
0.5% NP-40, 0.25% Triton X-100, protease inhibitors) followed by rotation at 4ºC for 15 min. 
Cells were spun at 1350xg for 5 min, and resuspended in cold Lysis Buffer 2 (107 cell/mL; 200 
mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, protease inhibitors) followed by 
rotation at room temperature for 10 min. Cells were spun at 1350xg for 5 min, and resuspended 
in sonication buffer (5x107 cell/mL; 10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.1% SDS, protease 
inhibitors). The suspensions were passed through an 18G needle to break up clumps, and the 
samples were then combined to a ratio of 2:1 HL60:S2 cells. 
 The combined samples were sonicated in a Bioruptor (Diagenode) for 15 cycles of 30 
sec on, 30 sec ice. The chromatin was centrifuged at 14,000xg for 12 min and the supernatant 
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was diluted 1:1 with dilution buffer (300 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl pH 8.0, 0.75% 
Triton X-100, 0.1% SDS).  Immunoprecipitation was performed using Protein A Dynabeads 
(Thermo Fisher) conjugated with rabbit IgG (Santa Cruz, sc-2027) or H4 acetyl (Millipore 06-
866, Lot 2491213). After overnight incubation at 4ºC with rotation, the beads were washed twice 
with low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-
HCl pH 8.1), twice with high salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 
mM NaCl, 20 mM Tris-HCl pH 8.1), once with LiCl wash buffer (0.25 M LiCl, 1% NP-40, 1% 
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1), and twice with TE buffer (10 mM Tris-HCl 
pH 8.1, 1 mM EDTA). Samples were eluted from beads by incubating in elution buffer (50 mM 
Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS) at 65ºC for 30 min. Crosslinks were reversed by 
incubating supernatant and input samples at 65ºC for 16 hr. Samples were treated with 0.2 
mg/mL RNase A for 1 hr at 37ºC, and 0.2 mg/mL Proteinase K for 2 hr at 42ºC. DNA was 
isolated using MinElute DNA purification columns (Qiagen).    
 
4.5.7 BRD4 Chromatin Immunoprecipitation and Illumina Library Preparation 
BRD4 ChIP was performed using 4.5x108 HL60 cells treated with 1 µM SAHA or 0.01% 
DMSO for 1 hr. Cells were then collected, washed in cold PBS, crosslinked as described above 
for 15 min at room temperature 15 min. After quenching the reaction with 0.125 M glycine for 5 
min, cells were washed twice in cold PBS and flash frozen. Pellets were resuspended in Lysis 
Buffer 1 as described above, incubated at 4ºC for 15 min and centrifuged. Pellets were 
resuspended in Lysis Buffer 2 as described above, incubated at room temperature for 10 min 
and centrifuged. Pellets were then resuspended in sonication buffer (4x107 cell/mL; 10 mM Tris-
HCl pH8.0, 0.1% SDS,  100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% deoxycholate, 0.5% 
Sarkosyl L, protease inhibitors). Sonication was performed using a Bioruptor (Diagenode) for 35 
cycles of 30 sec on, 30 sec ice. The chromatin was centrifuged at 14,000xg for 10 min and the 
supernatant was diluted 1:1 with dilution buffer. Immunoprecipitation was performed using 
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Protein A Dynabeads conjugated to rabbit IgG or BRD4 antibody (Bethyl Labs A301-985A100, 
Lot 4). After overnight incubation at 4ºC with rotation, beads were washed, crosslinks were 
reversed, samples were treated with RNaseA and Proteinase K and eluted as described above. 
DNA was isolated using MinElute DNA purification columns. 
 
4.5.8 Illumina ChIP Library Preparation and Sequencing 
Sequencing libraries were generated from DNA enriched by ChIP following the 
manufacturer’s specification for the Tru-Seq library preparation kit (Illumina). Following library 
generation, single end sequencing was performed using Illumina HiSeq2000 (UNC Chapel Hill 
High Throughput Sequencing Facility). 
 
4.5.9 Peptide microarray 
Peptide arrays were synthesized as previously described (Fuchs 2011, Rothbart 2012). 
Bromodomains were cloned into pGEX-6P1 vectors, expressed in BL21 E. coli, and purified 
using batch purification on glutathione resin (Pierce). Proteins were eluted and stored in PBS. 
Domains were arrays as previously described using GST antibody (Sigma) to detect the bound 
protein (138). H4 acetyl antibody (Millipore 06-866, Lot 2491213) specificity was determined as 
previously described (139) using 1:2000 dilution in PBS with 0.1% Tween-20 and incubation for 
1 hr at room temperature. After incubation with domains or antibody, arrays were washed in 
cold PBS, incubated in secondary antibody and scanned using a Typhoon. After normalizing the 
average signal of triplicate spots to the peptide with the highest signal, heat maps were 






4.5.10 H4 Acetyl ChIP-seq Alignment and Normalization 
Single end 50-bp reads were filtered using TagDust (101). ChIP-Rx normalization was 
performed as described in (125). Briefly, reads were first aligned to the Drosophila dm3 genome 
using Bowtie (102). Unmapped reads were then aligned to the human hg19 genome using 
Bowtie and reads were normalized to Drosophila mapped read counts (Fig S2B). Correlation 
between replicates was assessed by Pearson correlation using wig correlate (UCSC).  
 
4.5.11 H4ac ChIP-seq Genomic Window Analysis  
To generate differential windows, input signal was subtracted from ChIP signal. Signal 
was then averaged across 300bp sliding windows offset by 100bp. Differential windows were 
identified using DESEQ2 (136). Windows with significant enrichment were merged and 
identified as a peak. H4ac signal in differential windows was then plotted as a fraction of 
SAHA/DMSO to generate histogram of fold-change after SAHA treatment. Smoothed scatter 
plots of H4ac signal in differential windows were generated using R as average signal over 
window size. Enrichment for genomic features in differential windows was analyzed by CEAS 
(126). 
 
4.5.12 BRD4 ChIP Peak Detection and Analyses 
Single end 50-bp reads were filtered using TagDust (101) and aligned to hg19 using 
Bowtie (102). Peaks were called with MACS2 (141). BEDTools (142) was used to merge 
overlapping peaks and to identify shared and unique peaks. Enrichment for genomic features 
was analyzed using CEAS (126). Each peak was matched with its closest genes within 1000kb 
using the Genomic Regions Enrichment of Annotations Tool (GREAT) (143). Genes were 








CHAPTER 5: CONCLUSIONS AND DISCUSSION 
 
5.1 Overall Summary 
DNA compaction is essential for packaging the genome into an individual cell. This 
compaction, however, generates challenges for accessing the underlying DNA. The cell has 
devised mechanisms for regulating chromatin structure through the use of histone modifications 
and chromatin remodelers. The BD-Ac interaction is one of the most widespread and studied 
interactions. However, there is still much unknown about how multiple bromodomains engage 
acetylation and the consequence of disrupting this interaction. Because of the widespread 
nature of the BD-acetyl interaction, disrupting the BD-acetyl bond can have widespread 
consequences, making both the BD and acetyl potential therapeutic targets. This dissertation 
sought to better understand (1) how multiple BDs function in tandem to mediate interactions 
with acetylation (2) how BD mutations affect chromatin interactions (3) how loss of a 
bromodomain containing subunit of a chromatin remodeler alters chromatin organization and 
gene expression and (4) how altering acetylation through histone deacetylase inhibitors alters 
acetylation and bromodomain targeting genome-wide.  
The focus of this work has been on the interaction between BDs and acetylation and the 
mechanism behind a drug targeting this interaction. In Chapter 1, the known roles of the BD-Ac 
are discussed. In Chapter 2, we discuss how a bromodomain engages chromatin and the effect 
of BD mutations on chromatin interactions using the chromatin remodeling subunit, PBRM1. In 
Chapter 3, the effect of PBRM1 loss on chromatin organization and gene expression is 
examined. Lastly, in Chapter 4, we examine how a drug altering the acetyl landscape functions 
and how it may be altering the bromodomain-acetyl interaction.  
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5.2 Functionality of the six tandem PBRM1 bromodomains on histone PTM recognition 
The chromatin remodeling subunit, PBRM1, was used to examine how a bromodomain 
engages acetylation. PBRM1 was a prime candidate for studying interactions with chromatin 
because of its six tandem bromodomains. The presence of six BDs allowed us to assess 
binding of individual BDs, while examining the influence of neighboring BDs on binding 
interactions. Additionally, little is known about the function of PBRM1, however, its frequent loss 
in ccRCC suggests it plays an important role in cellular homeostasis. We hypothesized that a 
better understanding of how PBRM1 targets chromatin and where it targets could provide a 
better understanding of how its loss may be promoting tumorigenesis. Using PBRM1, we 
demonstrated that, while many BDs share a conserved structural fold, the function of BDs can 
vary widely even within an individual protein. This was not a complete surprise given the role of 
individual BDs in a diverse array of proteins. Surprising, however, was the finding that 
neighboring BDs could have different effects on the binding of an individual BD.  
Select PBRM1 BDs (BD1 and BD5) were unable to individually bind acetylated 
nucleosomes but when in the context of a neighboring BD, enhanced binding interactions. The 
use of tandem reader domains to enhance binding interactions has been previously reported for 
various proteins, including TAF1 and Dpf3. TAF1, a subunit of the TFIID basal transcription 
factor, contains two BDs that prefer diacetylated peptides to monoacetylated peptides(144). 
Dpf3, a member of the BAF chromatin remodeling complex, contains two PHD domains that 
mediate interactions with H3K14ac through a binding pocket formed from the surface groove 
between the two PHD domains (145). While our study uncovered the BDs driving the histone 
interactions and the BDs enhancing these interactions, future studies are needed to better 
understand how these interactions are physically occurring. Crystallization of the tandem 
domains in complex with an H3K14ac and/or a H3K4me3 peptide will help to clarify how these 
BDs are engaging nucleosomes.  
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Surprisingly, we found that one bromodomain (BD3) was able to attenuate binding of its 
neighboring BDs. A previous study focusing on Rsc4, a subunit of the yeast remodeler RSC, 
demonstrated the ability of the two BDs to work together to regulate binding to histone PTMs 
(57). BD2 of Rsc4 binds to H3K14ac, while BD1 binds acetylated K25 of Rsc4 itself. Acetylation 
of K25 inhibits binding to H3K14ac functioning as an autoregulatory mechanism. While our 
study identified the potential inhibitory effect of BD3, future studies are necessary to understand 
the mechanism behind this inhibitory effect. It is possible that the inhibition is due to expression 
of tandem BDs instead of full-length PBRM1. Therefore, to better understand the inhibitory 
effect of BD3, it should be studied in the context of full-length PBRM1.  
 
5.3 PBRM1 bromodomain interactions with methylation 
One of the most striking findings from our study was the ability of BD2 and BD4 to 
directly bind H3K4me3. Prior to this study BDs have only been shown to interact with 
acetylation.  This finding could change the way we view bromodomains and could open the 
doors to how and where bromodomains are functioning genome-wide. Additional studies, 
however, are necessary to fully elucidate this binding interaction. Previous studies have used 
NMR to show the binding of PBRM1 BD2 to H3K14ac (62). This would not be the first time a 
reader domain that was thought to mediate interactions with solely one type of histone PTM 
gained an additional binding moiety. The PHD domain was initially thought to mediate 
interactions solely with methylated residues, however, over a decade after it was discovered, 
findings suggest it can also mediate interactions with acetylation (146). To fully elucidate 
whether PBRM1 can in fact interact with methyl groups, a similar study should be performed 
using BD2 and BD4 with an H3K4me3 peptide. This would also help elucidate through which 
amino acids this interaction is mediated. Overlapping PBRM1 and H3K4me3 ChIP-seq 
experiments would also help to further clarify the interaction between BDs and methylation, 
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while providing a platform to assess changes in PBRM1 targeting associated with PBRM1 
mutations.  
 
5.4 The role of PBRM1 at promoters and enhancers 
In Chapter 2, we demonstrated that the PBRM1 BDs preferentially recognized H3K14ac 
and H3K4me3, marks frequently found at promoters. In Chapter 3, we showed that PBRM1 loss 
increased chromatin accessibility at promoters by FAIRE-seq, supporting our previous findings 
that suggest PBRM1 functions at promoters. However, in Chapter 3 we also claim that PBRM1 
loss altered enhancer formation, leading to both the gain and loss of enhancers. One possible 
explanation for how PBRM1 affects promoters and enhancers is through a looping mechanism 
between promoters and enhancers. We suggest that PBRM1 binds promoters as part of the 
PBAF complex, and loops to form interactions with enhancers. To test this chromosome 
conformation capture assays, such as HiChIP(147), should be performed for marks of 
enhancers (H3K27ac and H3K4me1) in cells with and without PBRM1. If PBRM1 is involved in 
promoter-enhancer looping, PBRM1 loss will diminish detected interactions.  These interactions 
with enhancers may be either direct or indirect and mediated through interactions with other 
proteins, including other chromatin remodelers.  
 
5.5 PBRM1 missense mutations and chromatin recognition 
The majority of ccRCC mutations are nonsense mutations, resulting in loss of function. 
Over 15 percent of PBRM1 mutations, however, are missense mutations that may retain partial 
function. In Chapter 2, we demonstrated that mutations within the critical BDs (BD2 and BD4) 
attenuated PBRM1 interactions with chromatin and altered cell proliferation. We hypothesize 
that the missense mutations may be altering the targeting specificity of PBRM1. To test whether 
PBRM1 missense mutations alter the targeting of PBRM1, which may be playing  a role in 
altering cell proliferation, ChIP-seq experiments for PBRM1 and PBRM1 mutants are necessary. 
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From these data we could elucidate whether PBRM1 missense mutations retarget PBRM1 to 
different genomic regions or simply decrease the ability of PBRM1 to bind chromatin.  
 
5.6 Effect of HDACi on the acetylome and BD targeting 
In Chapter 1 we highlighted the tight regulation between the addition and removal of 
acetylation in order to regulate gene expression. In Chapter 4, we examined the effect of 
disrupting this regulation by inhibition HDACs on acetylation and bromodomain targeting. One of 
the most striking findings from our study was the degree of hyperacetylation that occurred after 
HDACi. Under normal conditions, the H4 tail is unacetylated or mono-acetylated, however, after 
HDACi almost after HDACi almost ninety percent of the genome exhibits some form of H4 
acetylation. Under normal conditions there is virtually no H4 tetra-acetylation, however, after 
HDACi almost a quarter of the genome showed H4 tetra-acetylation. Using proteomics, we 
showed that many proteins, including many members of the pre-initiation complex, recognize 
H4 tetra-acetylation. Together these data suggest that HDACi has a wide-spread effect on 
acetylation levels that can great effect the binding of BD-containing proteins.  
We further assessed the effect of BRD4 binding in response to HDACi because previous 
studies had found that HDACi and inhibition of BRD4 through a BETi had similar phenotypic 
responses. This was, at first, seemingly contradictory because we hypothesized that HDACi 
would increase the number of BRD4 binding sites, while BETi would decrease the number of 
binding sites. Interestingly, however, our findings suggest that HDACi, while increasing the 
number of BRD4 binding sites decreases the amount of BRD4 bound at each of the binding 
sites. This suggests that HDACi dilutes the presence of BRD4 at target sites and may in fact be 
acting similarly to BETi in decreasing the binding of BRD4 at target sites. binding. Future studies 




5.7 HDAC inhibitors and transcription  
Previous studies have demonstrated that HDAC inhibition results in the dysregulation of 
only 2-10 percent of all genes (20). This was, at first, surprising considering acetylation is 
commonly associated with enhanced transcription. Our work in Chapter 4, however, 
demonstrates that HDAC inhibitors do not induce de novo acetylation but rather target sites of 
pre-existing acetylation. Transcriptionally repressed genes are not associated with acetylation 
and are, therefore, not a target of HDACi. Therefore, we should not expect HDACi to induce 
transcription of the vast majority of genes. We show that highly expressed genes have high 
levels of acetylation in the promoter regions and previous studies have demonstrated high 
levels of HDACs in the gene body of highly transcribed genes, providing a quick on/off 
mechanism. HDACi would, therefore, lead to an increase in already highly expressed genes.  
 
5.8 In conclusion 
The bromodomain-acetyl interaction is one of the most prevalent and widely studied 
interactions. BD-containing proteins are involved in a wide array of biological functions, 
including chromatin remodeling and protein scaffolding. In this work we examined 1) how a BD 
interacts with histone PTMs 2) how loss of a BD-containing protein involved in chromatin 
remodeling results in altered chromatin organization and gene expression and 3) how 
dysregulating acetyl levels alters BD targeting. Understanding these components of the BD-Ac 
interaction can help to better understand how dysregulation of BD-containing proteins can affect 
the genome-wide landscape and in return help to develop more targeted therapies.  
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Supplementary Figure A.1: BD1, BD3, and BD5 conserved residues located away from 
histone interacting region. (A) Sequence alignment of PBRM1 bromodomains. Shading and 
arrows reflect the degree of conservation between bromodomains. Residues commonly mutated 
in ccRCC are shown with red and blue text. Structural elements of a bromodomain are indicated 
above the alignments. Conserved residues are overlaid on an NMR-derived secondary structure 
of PBRM1 BD2 in association with histone H3 tail with residues shared between (B) only BD1 





Supplementary Figure A.2: Assessment of cellular and recombinant nucleosomes. (A) In 
nucleo digestion of HEK293 cells with varying concentrations of MNase. (B) Validation of 
modified recombinant nucleosomes by Western blot. (C) Coomassie stained SDS-PAGE gel of 




Supplementary Figure A.3: PBRM1 BD2/4 mutant is less stable on chromatin. Percent of 
PBRM1 eluted as calculated by the sum of PBRM1 eluted from 50 mM, 100 mM and 200 mM 
NaCl plotted over total PBRM1 eluted.  
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APPENDIX B: HDAC INHIBITOR ANALYSES   
 
 
Supplementary Figure B.1:  Sodium butyrate leads to H3 hyperacetylation. Bar graph 
depicting percent of individual peptides identified by mass spectrometry for A) H3 (3-8), B) H3 












































































Supplementary Figure B.2: ChIP-RX shows genome-wide increase in H4 polyacetylation. 
A) Fraction of Drosophila reads in H4ac ChIP replicates. B) Peptide microarrays of H4 
polyacetyl antibody showing relative binding to the indicated peptides. C) Histogram of 
log2(SAHA/DMSO) showing a range of increase in H4ac. D) Pearson’s correlation between 
H4ac ChIP replicates. E)  Density plot showing the log2 fold change of H3K27ac vs H4ac signal 
before (left) and after (right) SAHA treatment in 500bp windows. (F) Fraction of super-
enhancers called with H4ac for DMSO and SAHA treatments overlapping H3K27ac called 
super-enhancers.  
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Supplementary Figure B.3: Gene expression changes associated with HDACi treatment 
by RNA-seq. A) Scatter plot of RPKM for 1 hr and 2 hr changes in gene expression after SAHA 
treatment. B) MA-plot comparing the log2 mean of normalized read counts to the log2 fold 
change between SAHA and DMSO treatments where the adjusted p-value is £ 0.05. The color 
of each point represents the magnitude of adjusted p-value from 0 to 0.05. C) Gene ontology 
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